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Abstract 
Hydroxypropyl methylcellulose (HPMC) capsules are a new type of hard two-
piece capsules developed as an alternative to classic hard two-piece gelatine 
capsules. HPMC capsules have several technical advantages over gelatine 
capsules, e.g. lower moisture content, chemical inertness and an ability to 
maintain mechanical integrity under very low moisture conditions. In addition, 
HPMC capsules are made of plant-derived material, whereas the gelatine capsules 
are of animal origin (swine and bovine). This eliminates the problems relating to 
religious and vegetarian dietary restrictions.  
 There is not enough information available about the bioavailability of drugs 
from HPMC capsules to be regarded as interchangeable with gelatine capsules. 
Therefore, the main objective of the present thesis was to evaluate the 
biopharmaceutical properties of HPMC capsules made by Shionogi Qualicaps 
S.A. in comparison with hard gelatine capsules. Both in vitro drug release and in 
vivo oral and rectal bioavailability of the model drugs, ibuprofen and 
metoclopramide hydrochloride, were investigated. The capsules were diluted with 
either lactose or HPMC powders of different viscosities. 
The overall conclusion of the studies reported here was that the HPMC and 
gelatine capsule shells could be regarded as interchangeable for both oral and 
rectal administration regardless of the model drug or the diluent used. However, 
after the rectal administration of the capsules, the time lapse to the 
commencement of drug absorption was always greater for the HPMC capsules 
than for the corresponding gelatine capsules. Therefore, the rectally administered 
HPMC capsules could be regarded as an alternative to gelatine capsules if rapid 
onset of action is not needed. In addition, the tendency of the HPMC capsules to 
stick to the oesophagus turned out to be high, making further investigation of this 
phenomenon necessary.  
The orally and rectally administered HPMC and gelatine capsules diluted with 
HPMC powders fulfilled the basic requirements of a prolonged-release 
formulation. The release of the model drugs could be controlled also by changing 
the viscosity grade of the HPMC polymer when the capsules were administered 
orally, but not when the rectal route was used. The hard capsules proved to be of 
value as a rectal dosage form, although attention should be paid to the technique 
of insertion and to the time lapse to the onset of drug absorption, which was about 
30 min for the gelatine capsules and about 60 min for the HPMC capsules.  
 v 
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1. Introduction 
Hard two-piece capsules were first invented in 1846 when Parisian pharmacist 
J.C. Lehuby was granted French Patent 4435 for “Mes envelopes 
médicamenteuses” (Jones, 1987). These capsules were made of starch or tapioca. 
Three additions to the original patent were granted in the following four years, 
extending the range of raw materials to carragheen, various gelatines (including 
animal gelatine) and gums. The sole use of animal gelatine for making hard two-
piece capsules was first described in British Patent 11,937, which was granted to 
J. Murdoch in 1848. Nowadays, hard gelatine capsule is a widely popular oral 
dosage form due to the relative ease of manufacture and flexibility of size to 
accommodate a range of fill weights.  
Hard gelatine capsules have some disadvantages owing to the raw material. 
Gelatine capsule shells have 13-15% water content and therefore may not be 
suitable for water-unstable drugs. They also loose their mechanical strength and 
become brittle when the moisture content of the capsule shell is decreased, e.g. 
when the capsule contains strongly hygroscopic material (Kontny and Mulski, 
1989). Furthermore, some drugs react with amino groups of the gelatine protein 
during storage under severe conditions, causing the gelatine to cross-link and 
reducing the solubility of the capsule shell (Digenis et al., 1994). Gelatine for 
capsules is mainly of bovine origin, which creates a theoretical risk of 
transmitting bovine spongiform encephalopathy (BSE) via capsules (U.S. 
Department of Health and Human Services, 1997; EMEA, 2001). In addition, 
gelatine products from bovine and swine sources are sometimes avoided as a 
result of religious or vegetarian dietary restrictions. To overcome these problems, 
hard two-piece capsules made of only plant-derived materials, i.e. hydroxypropyl 
methylcellulose (HPMC), have been developed by Shionogi Qualicaps S.A. 
(HPMC capsule), Capsugel Division of Pfizer Inc. (Vcaps), Natural Capsules 
Ltd. (Cellulose Capsule) and Associated Capsules Ltd. (Naturecaps). 
The physicochemical properties of the HPMC capsules (Shionogi Qualicaps 
S.A.) compared with corresponding gelatine capsules have been sufficiently 
described in the literature by the manufacturer (Ogura et al., 1998). The 
biopharmaceutical properties of the capsules were also described in the same 
publication, but to a far more limited extent. No other studies on the 
bioavailability of drugs in humans from the two different capsule shells could be 
found in the literature. Thus, there was an evident need for further 
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biopharmaceutical studies in human volunteers before the HPMC and gelatine 
capsule shells could be regarded as interchangeable. The main objective of the 
present thesis, therefore, was to widen knowledge of the biopharmaceutical 
properties of the HPMC capsules made by Shionogi Qualicaps S.A. The HPMC 
capsules were compared with classic hard two-piece gelatine capsules of the same 
size and both the in vitro drug release and the in vivo drug absorption following 
oral and rectal administration were investigated. Rectal administration was 
evaluated, because it is known that in hospitals commercial hard gelatine capsules 
are sometimes used rectally (Storey and Trumble, 1992), although they are not – 
contrary to some soft gelatine capsules – officially accepted for rectal use. Both 
the HPMC and gelatine capsules contained two model drugs of different water 
solubilities, ibuprofen or metoclopramide hydrochloride, and lactose or 
hydroxypropyl methylcellulose powder of different viscosities as diluents to 
obtain immediate-release or sustained-release formulations. In addition, gamma 
scintigraphic method was utilised in order to gain a better understanding of the 
fate of the HPMC capsules in the human gastrointestinal (GI) tract. 
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2. Review of literature 
2.1. Hydroxypropyl methylcellulose capsules 
2.1.1. Manufacture 
HPMC capsules (Shionogi Qualicaps S.A., Japan) are manufactured by the same 
dipping and forming method that is applied in the manufacture of classic hard 
gelatine capsules (Pat.U.S. 5,756,123). Shaped pins are dipped into an aqueous 
solution comprising 18-28% w/w HPMC 2910 having 28-30% methoxy and 7-
12% hydroxypropoxy group and a viscosity of 2.4-5.4⋅10-6 m2/s (measured as a 
2% aqueous solution at 20°C) as a base, 0.01-0.09% w/w carrageenan as a gelling 
agent, and 0.05-0.6% w/w potassium and/or calcium ions as a co-gelling agent. 
Small amounts of carrageenan and potassium and/or calcium ions are added to the 
HPMC solution to enable gelling at 48-55°C, since HPMC alone gels at 
temperatures below 60°C. After dipping, the HPMC film is gelled, dried, trimmed 
and removed from the pins. The body and cap pieces are then joined. The finished 
HPMC capsule shells comprise 79.6-98.7% w/w of HPMC 2910, 0.03-0.5% w/w 
of carrageenan, 0.14-3.19% w/w of potassium and/or calcium ions and 2-5% w/w 
of water. 
2.1.2. Physicochemical properties compared with hard 
gelatine capsules 
HPMC capsules are odourless and flexible (Pat.U.S. 5,756,123). Their appearance 
corresponds to that of gelatine capsules, except that the surface of HPMC capsules 
is matt, whereas the surface of gelatine capsules is lustrous. The physical 
properties of HPMC capsules compared to gelatine capsules are presented in 
Table 1 (Ogura et al., 1998). The main differences in the physicochemical 
properties between HPMC and gelatine capsules are related to their moisture 
content, which is 2-5% for HPMC capsules and 13-15% for gelatine capsules 
(Table 1). The relationship between the brittleness and moisture content of HPMC 
and gelatine capsules has been demonstrated using a hardness tester (Ogura et al., 
1998). The percentage of broken gelatine capsules increased to almost 100% as 
the moisture content of the capsule shell decreased below 10%. In contrast, 
HPMC capsules remained undamaged even at moisture levels of only 2%. This 
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difference between HPMC and gelatine capsules could be of significance in 
practice if the drug filled in the capsule is strongly hygroscopic. 
Table 1. Physical properties of HPMC and gelatine capsules (Ogura et al., 1998).  
Capsule material  HPMC Gelatine 
Moisture content 2-5% 13-15% 
Water vapour permeability Low Low 
Substrate for protease No Yes 
Maillard reaction with drug fill No Yes 
Deformation by heat > 80°C  > 60°C 
Water dissolution at room temperature Soluble Insoluble  
Static Low High 
Light degradation No Possible 
 
The stability of a water-unstable drug in HPMC and gelatine capsules has been 
tested with acetylsalicylic acid (Ogura et al., 1998). HPMC and gelatine capsules 
filled with acetylsalicylic acid alone were stored at 60°C for two weeks. The drug 
content did not decrease to less than 95% of its initial concentration when stored 
in the HPMC capsules, whereas it decreased to 85% of its initial concentration 
when stored in the gelatine capsules, apparently as a result of hydrolysis. Thus, 
due to the naturally low moisture content of the HPMC capsule shells, they are 
more suitable than gelatine capsules for use with formulations containing water-
unstable drugs.   
Another notable difference between HPMC and gelatine capsule shells is that 
HPMC capsule shells are compatible with most filling materials, since the only 
incompatibility known for HPMC is the interaction between some oxidizing 
agents (Harwood, 2000). Gelatine, on the other hand, has chemically reactive 
groups. Ogura and co-workers (1998) filled HPMC and gelatine capsules with 
ascorbic acid and packed them in polyethylene bottles without a desiccant, and 
stored at 40°C/75% relative humidity for two months. The gelatine capsules were 
dyed brown, whereas the colour of the HPMC capsules did not change. In both 
cases the colour of the ascorbic acid in the capsules did not change, indicating that 
the discoloration was the result of a reaction between the ascorbic acid and the 
gelatine shell (called Maillard reaction). 
The dissolution of gelatine capsule shells can be incomplete and slow if the 
capsules contain drugs having aldehyde groups or producing aldehydes on 
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decomposition, which promote cross-linking between gelatine proteins and form a 
thin insoluble membrane called a pellicle (Carstensen and Rhodes, 1993; Digenis 
et al., 1994). This has been demonstrated with spiramycin, a macrolide antibiotic 
known to cause insolubilisation of gelatine capsules (Ogura et al., 1998). 
Spiramycin was filled into HPMC and gelatine capsules and stored at 60°C/75% 
relative humidity for ten days. After storage, the disintegration properties of the 
HPMC capsules remained unaffected, whereas the properties of the gelatine 
capsules changed and they did not disintegrate.  
Chiwele and co-workers (2000) studied the shell dissolution properties of 
empty gelatine and HPMC capsules after storage under humid tropical conditions 
(37°C/75% relative humidity) for 24 h and after storage under ambient room 
conditions. They used the method described by Jones and Cole (1971), which 
consists of placing a steel ball bearing inside the capsule, suspending the capsule 
body in the test solution and measuring the time for it to fall from the capsule. The 
dissolution medium was artificial gastric or intestinal juice (BP). The temperature 
of the medium was in the range of 10° to 55 °C. Storage under humid tropical 
conditions did not affect the dissolution properties of the gelatine capsules 
regardless of the dissolution medium, whereas the dissolution time of the HPMC 
capsule shells was unaffected only in artificial gastric juice. In artificial intestinal 
juice the shell dissolution times of the HPMC capsules were significantly reduced 
for temperatures between 10° and 30°C, whereas above 37°C the shell dissolution 
times were increased. It was suggested that the HPMC capsules were hydrated 
during storage, which might have caused the slower water penetration through the 
hydrated material and, thus, slower dissolution time of the capsule shell. The 
reason for the different shell dissolution times of the HPMC capsules in the 
different dissolution media and at different temperatures was not discussed.  
Nevertheless, the authors pointed out that care should be taken when the HPMC 
capsules are exposed to hot and humid conditions.  
As was mentioned earlier, Ogura and co-workers (1998) did not notice any 
effect on the disintegration properties of the HPMC capsules filled with 
spiramycin when stored at 60°C and 75% relative humidity for ten days. 
However, they used a standard pharmacopoeial disintegration test, which is fairly 
drastic and does not determine the shell dissolution time and the disintegration of 
the powder plug separately (Chiwele et al., 2000). In the method used by Chiwele 
and co-workers (2000), on the other hand, the filling material (steel ball bearing) 
did not affect the shell dissolution time. 
The study of Chiwele and co-workers (2000) further revealed that the HPMC 
capsule shells dissolved rapidly in water (pH 5.8) and 0.1 M hydrochloric acid 
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(pH 1.0) in the temperature range of 10 to 55°C. The gelatine capsule shells, on 
the other hand, did not dissolve at temperatures below 30°C in the same 
dissolution medium, and the dissolution time was dependent on the temperature.  
2.1.3. In vitro drug release 
Three studies (other than those included in this thesis) describing the in vitro drug 
release properties of HPMC capsules (Shionogi Qualicaps S.A.) compared to 
corresponding gelatine capsules can currently be found in the literature (Ogura et 
al., 1998; Podczeck and Jones, 2002; Wu et al., 2003). Ogura and co-workers 
(1998) studied the release of cephalexin from HPMC and gelatine capsules in 
solutions having pH 1.2, 4.0 or 6.8. The procedure applied was the paddle method 
described in the Japanese Pharmacopoeia (JP) and the speed of rotation was 100 
rpm. There were no differences in the dissolution profiles between the HPMC and 
gelatine capsules when the pH of the solution was 1.2 or 4.0. When the 
dissolution medium was the JP “second test fluid” with pH 6.8, the dissolution 
times of cephalexin were approximately 5 min longer from HPMC capsules than 
from gelatine capsules. This was supposed to be due to the presence of potassium 
in the medium, which promotes the gelation of carrageenan. Thus, the HPMC 
capsule shell formed a persistence gel membrane around the drug fill. When the 
dissolution medium was changed to potassium-free buffer pH 6.8, there were no 
differences between the two different capsule shells. Since the cation 
concentration in the gut is low, it was suggested that pharmacopoeial buffer 
solutions that do not contain potassium ions could be considered acceptable 
alternatives for determining in vitro drug dissolution rates from HPMC capsules. 
Podczeck and Jones (2002) investigated the release of theophylline from 
HPMC capsules compared with hard gelatine capsules. The capsules contained 
either the model drug only or the drug and lactose or microfine cellulose as a 
diluent, and different fill weights and tamping forces were utilized. The 
dissolution tests were carried out using distilled water at 37°C and a paddle speed 
of 50 rpm. The amount of theophylline released after 60 min from the different 
HPMC capsule formulations was always greater than from the corresponding 
gelatine capsules. Also the release rate was generally greater from the HPMC 
capsules than from the gelatine capsules. This was suggested to be due to the 
dissolution properties of HPMC capsule shells. HPMC capsule shells dissolve 
evenly and simultaneously across the whole shell, whereas gelatine capsules 
dissolve first from the shoulders, and only later across the whole body. Thus, the 
whole powder plug filled in an HPMC capsule will be subjected to the dissolution 
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medium earlier. The authors concluded that a change from gelatine hard shell 
capsules to HPMC hard shell capsules should not pose problems with respect to 
drug absorption and bioavailability. 
Wu and co-workers (2003) studied the release of an investigational drug, BMS-
309403, (poorly water-soluble weak acid) from size 0 gelatine and HPMC 
capsules. The capsules contained either 50 or 200 mg of the granulated drug and 
the total fill weights were 90 and 360 mg, respectively. It was estimated that a 90 
mg fill weight only occupied a volume of about 20% of the capsule body, whereas 
360 mg occupied about 80%. The dissolution tests were carried out using the USP 
paddle method (60 rpm). The dissolution medium was 0.5% sodium lauryl sulfate 
in 0.1 M sodium phosphate buffer, pH 6.8 (37°C). The results showed that when 
the capsule shell was gelatine, the 50 mg capsules surprisingly dissolved at a 
much lower rate than the 200 mg capsules. It was observed that the shells of the 
50 mg gelatine capsules softened and collapsed during the first 10 min of the 
dissolution test, occluding the granules and retarding the drug release. This was 
not observed when the gelatine capsules contained 200 mg of the drug; the 
capsule shells burst open within the first 10 min. When the capsule shell type was 
changed to HPMC, the 50 mg capsules dissolved slightly faster than the 200 mg 
capsules and the HPMC capsule shells did not collapse onto the granulation. 
However, both HPMC capsule strengths dissolved more slowly during the first 10 
to 20 min than the corresponding gelatine capsules, which was due to the swelling 
and expansion of the HPMC capsule shells without leaking much granulation 
during the first 10 min.  
2.1.4. Biopharmaceutical properties 
Studies describing the bioavailability of drugs from HPMC capsules (Shionogi 
Qualicaps S.A.) compared to gelatine capsules are limited to that of Ogura and co-
workers (1998) determining the oral bioavailability of cephalexin from HPMC 
capsules compared to gelatine capsules. The study was conducted with 6 healthy 
volunteers under fasting conditions. Concentrations versus time curves were 
similar between the HPMC and gelatine capsules and there were no significant 
differences in the pharmacokinetic parameters (AUC, Cmax and tmax) between these 
capsules. 
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2.2. Hydroxypropyl methylcellulose 
2.2.1. Manufacture 
The European Pharmacopoeia describes hydroxypropyl methylcellulose 
(hypromellose) as partly O-methylated and O-(2-hydroxypropylated) cellulose. 
The structural formula of HPMC is presented in Fig. 1.  
 
 
Figure 1. Structural formula of hydroxypropyl methylcellulose. The substituent R 
represents either a -H, -CH3, or a -CH2CH(CH3)OH. 
HPMC is an odourless, tasteless and inert hydrophilic polymer with no ionic 
charge. It is manufactured from purified cellulose, which is obtained from cotton 
linters or wood pulp (Harwood, 2000). The cellulose is first treated with sodium 
hydroxide solution to produce swollen alkali cellulose, which is chemically more 
reactive than the untreated cellulose. The alkali cellulose is then converted to 
methylhydroxypropyl ethers of cellulose by treating with chloromethane and 
propylene oxide. Finally, the fibrous reaction product is purified and ground to 
powder or granules.  
 
2.2.2. Physicochemical properties 
The physicochemical properties of HPMC (e.g. solubility, glass-transition 
temperature and viscosity) are affected by the ratio of methoxy and 
hydroxypropoxy groups and the molecular weight. The molecular weight of 
HPMC is approximately 10,000 to 1,500,000 (Harwood, 2000). There are several 
grades of HPMC polymers available on the market, which vary in viscosity and 
extent of substitution. The grades may be distinguished by a number indicative of 
the apparent viscosity, in mPa⋅s, of a 2% w/w aqueous solution at 20°C. The 
apparent viscosity serves as a measure of the average chain length of the polymer. 
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The USP presents four different types of HPMC polymers. They are classified 
according to their relative methoxy-group and hydroxypropoxy-group contents: 
HPMC 1828, HPMC 2208, HPMC 2906 and HPMC 2910. The first two numbers 
indicate the percentage of methoxy groups, the last two numbers the percentage of 
hydroxypropoxy groups, determined after drying at 105°C for two hours. The 
exact limits for the degree of substitution defining the respective HPMC types are 
given in Table 2. 
Table 2. USP specifications for different types of HPMC, classified according to their 
degree of methoxy and hydroxypropoxy substitution. 
Substitution type Methoxy (%)  Hydroxypropoxy (%) 
 Min. Max.  Min. Max. 
1828 16.5 20.0  23.0 32.0 
2208 19.0 24.0  4.0 12.0 
2906 27.0 30.0  4.0 7.5 
2910 28.0 30.0  7.0 12.0 
2.2.3. Applications in pharmaceutical formulation and 
technology 
HPMC is an extremely versatile material, which is widely used in pharmaceutical 
products. HPMC is primarily used as a binder, film coating and as a controlled-
release matrix in solid dosage forms (Rowe, 1980; Banker et al., 1981; Krycer et 
al., 1983a, b; Alderman, 1984; Harwood, 2000). Concentrations of 2-5% w/w may 
be used as a binder in either wet or dry granulation processes (Harwood, 2000). In 
film coating, concentrations of 2-20% are used, depending on the viscosity grade 
of the HPMC. In controlled-release matrix formulations, concentrations of 10-
80% may be used. In liquid dosage forms HPMC is used as a suspending and 
thickening agent and as an emulsifier. 
2.2.3.1. Hydroxypropyl methylcellulose in controlled-release 
formulations 
Controlled-release formulations have several benefits over conventional 
immediate-release formulations: controlled administration of a therapeutic dose at 
a desired delivery rate, constant blood levels of drugs, reduction of side effects, 
maintenance of therapeutic concentration also during the night, minimization of 
dosing frequency and enhancement of patient compliance (Ritschel, 1989). On the 
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other hand, controlled-release formulations also have some disadvantages, e.g. 
loss of efficacy when one or two doses are skipped and poor dosage form for 
drugs with inactivation by first-pass metabolism, extremely short or long 
elimination half-life and instability in the gastrointestinal environment.  
Hydrophilic matrix formulations are the most widely used of the numerous 
controlled-release dosage forms currently available and they have been employed 
in the pharmaceutical industry for over 40 years (Wichterle and Lim, 1960; 
Alderman, 1984; Ranga Rao and Padmalatha Devi, 1988; Ferrero Rodriguez et 
al., 2000). Of hydrophilic polymers, hydroxypropyl methylcellulose is the most 
popular material for the preparation of controlled-release dosage forms and it has 
been employed since the 1960s (Pat.U.S. 3,065,143; Lapidus and Lordi, 1966, 
1968; Huber et al., 1966; Huber and Christenson, 1968; Colombo, 1993; Hogan, 
1989; Ferrero Rodriguez et al., 2000). One of its most important characteristics is 
high swellability, which has a significant effect on the release kinetics of an 
incorporated drug. Also its ease of compression, non-toxic nature, ability to 
accommodate a large percentage of drugs, and the minimum influence of 
processing variables on the release of drugs from matrices are some of the reasons 
for its popularity (Vázquez et al., 1992).  
When the HPMC-based matrix formulation comes into contact with a 
thermodynamically compatible aqueous solvent, the solvent penetrates into the 
free spaces on the surface between the macromolecular chains. When the solvent 
has sufficiently entered into the matrix the characteristic glassy-rubbery transition 
temperature (Tg) of the polymer is decreased to the level of the experimental 
temperature and relaxation of the polymeric chains takes place (Siepmann and 
Peppas, 2001). The HPMC swells, causing the dimensions of the system to 
increase and the concentrations of the polymer and drug to change markedly. 
Water-soluble drugs dissolve in the solvent and diffuse out of the matrix 
according to concentration gradients. If the drug is poorly soluble in the solvent, 
dissolved and non-dissolved drug coexist within the polymer matrix and the non-
dissolved drug is not available for diffusion. Poorly soluble and insoluble drugs 
are mainly released when the outermost gel layer of the matrix is eroded. The 
erosion rate depends on the viscosity of the HPMC type used. The resulting drug 
release mechanism (Fickian, non-Fickian or Case II release) depends on the rates 
of drug diffusion, matrix relaxation and matrix erosion, and also on the dissolution 
of the drug in the gel (Lee, 1985; Colombo et al., 1999). Fickian diffusion is 
related to square root of time release, non-Fickian release is a combination of 
diffusion and polymer relaxation phenomena, and Case II release is characterised 
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by zero-order kinetics, i.e. the drug is released at a constant rate (Colombo et al., 
1990).  
Tablets are the most commonly used formulations in the design of HPMC-
based controlled-release dosage forms (Alderman, 1984), but also hard two-piece 
capsules containing either HPMC powder (Alderman, 1984; Ojantakanen, 1992; 
Ojantakanen et al., 1993; Eerikäinen et al., 1996; Leino et al., 1997) or HPMC-
based multiple units (Jalil and Ferdous, 1993; Cox et al., 1999; Pandey et al., 
2002; De Brabander et al., 2003) have been developed. There are some 
differences between the HPMC-based tablets and capsules when single-unit 
systems are considered. The size of the tablet may influence the drug release rate 
and the amount of polymer needed to obtain controlled release. Usually, the 
smaller the tablet is the greater the polymer content required (Alderman, 1984). 
Further, as the tablet size is increased, the drug release rate may be decreased due 
to changes in surface-to-volume ratios and in the degree of initial gel formation. 
On the other hand, the effect of capsule size on dissolution rates is less obvious 
and the release of drugs from different sized capsules varies only slightly 
(Alderman, 1984). The amount of HPMC polymer needed to achieve controlled 
drug release from capsule formulations is generally a little greater than that for 
tablet formulations exhibiting the same dissolution times. This is probably due to 
lower powder density in the capsules.  
A prerequisite for achieving controlled drug release from HPMC matrix 
formulations is fast formation of a gelatinous layer. In other words, the polymer 
must hydrate fast enough to form a gel layer before the contents of the 
formulation dissolve prematurely (Alderman, 1984; Ferrero Rodriguez et al., 
2000). In tablet formulations the hydration rate of HPMC type 2208 has turned 
out to be adequate, whereas types 2906 and 2910 do not hydrate fast enough to 
prevent the rapid disintegration and dissolution of tablet formulations (Alderman, 
1984; Ferrero Rodriguez et al., 2000). In capsule formulations all these HPMC 
types (2208, 2906 and 2910) exhibit adequate controlled drug release (Alderman, 
1984). 
2.2.3.2. Factors affecting drug release from hydroxypropyl 
methylcellulose type 2208 matrices 
Hydroxypropyl methylcellulose type 2208 having 19-24% methoxy and 4-12% 
hydroxypropoxy content is the most widely investigated polymer among the 
different types of HPMCs due to its faster hydration rate. There are several factors 
that can affect the release rate of a drug from HPMC type 2208-based matrices, 
e.g. HPMC viscosity grade, HPMC/drug ratio, HPMC and drug particle size, drug 
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solubility and formulation additives (Table 3) (Alderman, 1984; Hogan, 1989; 
Nokhodchi et al., 1999). Of these factors, the viscosity grade and concentration of 
the HPMC are those most often used in regulating drug release.  
Several studies have demonstrated that increasing the viscosity grade of HPMC 
type 2208 decreases the drug release rate from both tablet and hard capsule matrix 
formulations (Alderman, 1984; Ford et al., 1985a, b, c; Ojantakanen, 1992; Wan 
et al., 1992; Sung et al., 1996; Leino et al., 1997; Tros de Ilarduya et al., 1997; Li 
et al., 2003). This is due to the increase in the gel layer viscosity, causing the drug 
to diffuse slower through the gel layer. In addition, the greater the viscosity of the 
gel, the more resistant the gel is to dissolution and erosion. Consequently, the gel 
layer can be a controlling factor in drug release. In some studies, depending on the 
model drugs and formulations used, the release rate of the model drugs was not 
further decreased even though the HPMC type 2208 polymer was changed from a 
lower viscosity grade to a higher viscosity grade, e.g. from 4000 to 15,000 mPa⋅s 
or from 15,000 to 100,000 mPa⋅s (measured as a 2% w/w solution at 20°C) (Ford 
et al., 1985b, c; Ojantakanen et al., 1992; Sung et al., 1996). It was suggested that 
the HPMC matrix formulations studied have a “limiting HPMC viscosity”, i.e. the 
drug release rate no longer decreases when the viscosity grade is increased above 
a certain level, e.g. 4000 or 15,000 mPa⋅s (Sung et al., 1996). 
The drug/HPMC type 2208 ratio in matrix formulations affects the strength of 
the gel layer similarly to the viscosity grade of the HPMC polymer (Alderman, 
1984). When the concentration of the HPMC is increased, the viscous gel layer 
becomes stronger and more resistant to diffusion and erosion, causing the drug 
release rate to decrease. This phenomenon has been demonstrated in several 
studies conducted with matrix tablets containing water-soluble drugs, e.g. 
aminophylline (Ford et al., 1985c), potassium chloride (Salomon et al., 1979), 
promethazine hydrochloride (Ford et al., 1985b), propranolol hydrochloride (Ford 
et al., 1985c) and riboflavin (Alderman, 1984). Studies performed with hard 
capsule matrix formulations made of HPMC and utilising the effect of the 
drug/polymer ratio could not be found in the literature, probably because hard 
capsules are rarely used as single-unit controlled-release matrix formulations.  
When the drug is poorly water-soluble, an increase in HPMC concentration in 
matrix tablet does not necessarily lead to a decreased drug release rate in every 
situation. For example Ford and co-workers (1985a) have shown that the release 
rate of poorly water-soluble indomethacin was independent of the drug/HPMC 
type 2208 ratio when the viscosity of the polymer was 100 mPa⋅s. However, when 
the viscosity of the HPMC was changed to 4000, 15,000 or 100,000 mPa⋅s, the 
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release rate of indomethacin decreased as the HPMC content increased in the 
formulation. 
Table 3. The effect of various factors on drug release rate from HPMC type 2208-based 
tablet and capsule matrices. 
Factor Effect on drug release rate Reference 
     
HPMC viscosity grade 
 
As the viscosity grade of the HPMC 
polymer increases, the drug release 
rate decreases from both tablet and 
capsule matrices. 
Alderman, 1984; Ford et al., 1985a, b, c; 
Ojantakanen, 1992; Wan et al., 1992; 
Sung et al., 1996; Leino et al., 1997; 
Tros de Ilarduya et al., 1997; Li et al., 
2003  
HPMC/drug ratio 
 
As the concentration of the HPMC 
polymer increases or the concentration 
of drug decreases, the drug release rate 
decreases from tablet matrices. 
Salomon et al., 1979; Alderman, 1984; 
Ford et al., 1985b, c 
HPMC particle size 
 
The greater the particle size of the 
HPMC powder the greater is the drug 
release rate from HPMC tablet 
matrices. 
Alderman, 1984  
Drug particle size 
 
 
For water-insoluble drugs, a decrease 
in particle size increases the release 
rate from HPMC tablet matrices. For 
water-soluble drugs the effect of drug 
particle size is generally insignificant.  
Ford et al., 1985a, b, c; Tros de Ilarduya 
et al., 1997 
Drug solubility 
 
As the solubility of the drug increases, 
the release rate increases from HPMC 
tablet matrices. 
Colombo et al., 1995; Ferrero Rodriguez 
et al., 2000 
Formulation additives:   
Lactose and calcium 
phosphate 
Addition of lactose or calcium 
phosphate to HPMC tablet or capsule 
matrices increases the release rate of 
drug. 
Alderman, 1984; Ford et al., 1987; Sung 
et al., 1996; Nokhodchi et al., 1999 
Sodium carboxymethyl- 
cellulose (NaCMC) and 
microcrystalline cellulose 
Addition of NaCMC or 
microcrystalline cellulose to HPMC 
tablet matrices increases the drug 
release rate. The effect of these 
additives on capsule matrices is 
insignificant. 
Alderman, 1984; Nokhodchi et al., 1999 
Ionic surfactants 
 
Ionic surfactants decrease the release 
rate of drugs from HPMC tablet 
matrices if the surfactant and the drug 
are ionised and have opposite charges 
Feely and Davis, 1988 
Sodium lauryl sulphate 
  
Incorporation of sodium lauryl 
sulphate into HPMC tablet matrices 
increases the drug release 
Nokhodchi et al., 1999 
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The particle size and size distribution of the HPMC type 2208 powder affect the 
hydration rate of the HPMC, and thus the rate of gel formation and drug release 
from tablet matrices (Alderman, 1984). The coarser the HPMC powder particles 
are, the slower the gel formation and the greater the drug release rate. The effect 
of the particle size of the drug on the release rate from HPMC type 2208 matrices 
depends on the solubility of the drug (Ford et al., 1985a, b, c; Tros de Ilarduya et 
al., 1997). Ford and co-workers (1985a, b, c) noticed that decreasing the particle 
size of freely water-soluble drugs insignificantly affected the release rate, but 
when the model drug was poorly water-soluble, the release rates increased as the 
particle size of the drug decreased. Also Tros de Ilarduya et al. (1997) discovered 
that decreasing the particle size of water-insoluble oxazepam increased the release 
rate from HPMC matrices. These results indicate that for poorly water-soluble 
drugs not only the viscosity grade of the HPMC and the drug/HPMC ratio are 
important in controlling drug release but also the particle size of the drug is 
significant. 
Drug solubility also affects the release rate from HPMC matrices: increased 
solubility of the model drug results in a higher release rate from HPMC type 
2208-based tablet formulations (Colombo et al., 1995; Ferrero Rodriguez et al., 
2000). This is probably due to a higher concentration gradient through the gel 
layer, which increases the diffusion coefficient of the drug (Colombo et al., 1995). 
The water-solubility of drugs has an effect also on the release kinetics of drugs 
from HPMC type 2208 matrices (Ford et al., 1987; Ranga-Rao et al., 1990). 
Ranga Rao and co-workers (1990) studied the release of 23 drugs of various 
solubilities from HPMC type 2208 matrix tablets and reported that several 
sparingly, slightly and very slightly soluble drugs were released at a nearly zero-
order rate from the matrices, whereas the mode of release of water-soluble drugs 
was non-Fickian. Ford and co-workers (1987) reported similar observations when 
they studied the release of seven soluble and insoluble drugs from HPMC type 
2208 matrix tablets.  
Formulation additives also modify the release rate of drugs from HPMC 
matrices. The addition of lactose or calcium phosphate to HPMC type 2208-based 
tablet and capsule formulations generally increases the release rate of drugs 
(Alderman, 1984; Ford et al., 1987; Sung et al., 1996; Nokhodchi et al., 1999). 
Sodium carboxymethylcellulose (NaCMC) and microcrystalline cellulose are 
insoluble and swellable additives often used as fillers or disintegrants. When these 
are incorporated into HPMC type 2208-based tablet matrices, the gelatinous layer 
tends to expand, causing more of the drug to be released in the early stages of 
dissolution (Alderman, 1984; Nokhodchi et al., 1999). On the other hand, due to 
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the lower density of the powder plug in capsule matrix formulations, swellable, 
insoluble fillers have an insignificant effect on the drug dissolution profile from 
capsule matrices (Alderman, 1984). Also the effect of different surfactants on the 
release of drugs from HPMC type 2208-based matrix tablets has been evaluated 
(Feely and Davis, 1988; Nokhodchi et al., 1999). Ionic surfactants (e.g. sodium 
dodecylsulphate, n-hexadecylsulphate and n-octadecylsulphate) retarded the drug 
release only when these were ionised and had opposite charges (Feely and Davis, 
1988). Nokhodchi and co-workers (1999) have reported that incorporating sodium 
lauryl sulfate into HPMC matrices increased the drug release. This was probably 
due to the pores/channels that the surfactant formed in the matrix, thereby 
increasing the effective surface area by a method other than wetting.  
2.3. Rectal administration of hard capsules 
The rectal route of drug administration is feasible for the treatment of small 
children and very old people as well as patients who are not able to take oral 
medication due to nausea, vomiting, severe confusion or various GI diseases. In 
addition, drugs that are not suitable for oral administration could be administered 
rectally. For example some drugs may cause GI side effects when administered 
orally or they may be unstable at the pH of the upper GI tract. Orally administered 
drugs may also be metabolised by the various enzymes in the GI tract or during 
the first passage of the liver after administration. In addition, the rate of drug 
absorption from the rectum is not dependent on the gastric emptying rate or 
influenced by food. 
2.3.1. General considerations 
In order to understand the factors affecting rectal drug administration, it is 
important to be familiar with the anatomy and the physiology of the rectum. The 
human rectum is the distal part of the colon, forming the last 12 to 15 cm of the 
gastrointestinal tract (Moore, 1992). The rectal epithelium is mainly columnar or 
cuboidal and it is single-layered in the upper parts of the rectum and stratified in 
the lower parts. The epithelium contains numerous Globlet cells, but no villi or 
microvilli. Drugs are absorbed from the rectal mucosa via the paracellular and 
transcellular route and there are no active transport systems such as in the upper 
parts of the GI tract (Muranishi, 1984). Therefore, the main mechanism for rectal 
drug absorption is passive diffusion. The surface area of the rectum is about 200 
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to 400 cm2, about 10,000-fold smaller than that of the small intestine, partly due 
to the lack of the villi in the rectal epithelium. This means that the surface area of 
the rectum can be a rate-limiting factor in drug absorption. Moreover, the total 
fluid content in the rectum is only about 3 ml and is rather viscous, which limits 
the dissolution of poorly soluble drugs in the rectum (de Blaey and Tukker, 1988). 
The pH of the fluid is approximately 7.5 and it has poor buffer capacity. The 
environment of the rectum is, however, quite constant with respect to the amount 
and viscosity of the rectal fluid, its temperature and pH. Therefore, several drugs 
have exhibited reproducible absorption from the rectum and also rate control in 
rectal drug delivery is possible by using specific formulations (de Boer et al., 
1982; Breimer et al., 1985; van Hoogdalem et al., 1991a, b; de Boer and Breimer, 
1997). 
The rectum is drained by the superior, the middle and the inferior rectal veins 
(Moore, 1992). The superior rectal vein, perfusing the upper parts of the rectum, 
drains into the portal vein, and later into the liver, whereas the middle and the 
inferior rectal veins, perfusing the lower parts of the rectum, drain directly into the 
systemic veins. This means that it is possible to partially avoid hepatic first-pass 
metabolism of drugs via rectal administration, especially if the dosage form is 
administered to the lower parts of the rectum. However, the rectal vessels are 
connected with extensive anastomoses, which is a complicating factor in respect 
to the absorption of high-clearance drugs. The partial avoidance of the hepatic 
first-pass metabolism via rectal dosing has been demonstrated in humans with 
lidocaine (de Boer et al., 1979; de Leede et al., 1984a), metoclopramide (Hellstern 
et al., 1987), metopimazine (Herrstedt et al., 1996), 6-mercaptopurine (Kato et al., 
1992), morphine (Babul and Darke, 1993), metoprolol (de Stoppelaar et al., 
1999), propranolol (de Leede et al., 1984b), salbutamol (Kurosawa et al., 1993) 
and verapamil (Hammouda et al., 1996). The extent to which the first-pass 
metabolism can be avoided depends on several factors, e.g. the physicochemical 
properties of the drug and the vehicle, the absorption site in the rectum and the 
patient, because the venous drainage in the rectum can vary greatly between 
different individuals (de Boer et al., 1982).  
There are also other factors than those mentioned above that can affect the 
bioavailability of rectally administered drugs. For example faeces can 
mechanically prevent contact between the drug and the absorbing mucous (de 
Blaey and Tukker, 1988). However, the rectum is usually empty except when the 
faeces are temporarily transferred from the colon and are either defecated (when 
also the drug is removed) or transported back to the colon depending on the 
voluntary control of the subject. The rectum does not have a constant internal 
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volume; in an upright body position the intestinal organs press against the rectum, 
causing it to flatten. Therefore, the spreading of the rectal formulation and the 
subsequent absorption of the drug could be different in humans when walking 
than when prone. The rectal lumen also contains a lot of metabolising micro-
organisms that can affect the bioavailability of drugs, especially if the drug 
remains in the rectum for a relatively long time (de Boer et al., 1982). Also 
various properties of the drug substance and delivery system can affect the rectal 
bioavailability. Such properties are, for example, the solubility of the drug, the 
partition coefficient and particle size of the drug, the affinity and amount of the 
drug in the vehicle, the composition of the vehicle and the rheological, melting or 
dissolution properties of the vehicle (de Blaey and Tukker, 1988).  
2.3.2. Hard capsules 
Suppositories are the most common rectal dosage forms, but there are also rectal 
soft gelatine capsules on the market. So far, hard capsules have been used as a 
rectal dosage form only experimentally. Hard capsules have some advantages 
over suppositories and soft gelatine capsules. The manufacturing process for hard 
capsules is faster, cheaper and simpler than that for suppositories and soft 
capsules. Hard capsules could also be filled with solid materials in a retail or 
hospital pharmacy according to the specific prescription of a patient, whereas 
accurate dose adjustment or ex tempore preparation is not always possible with 
suppositories or soft capsules. Hard capsules could also be sealed to prevent 
leakage of the filling (Cadé et al., 1986), allowing greater flexibility in the choice 
of excipients: solids, semisolids and oily liquids could be encapsulated. Gelatine 
capsules become sticky when in contact with moisture, and thus the insertion of 
the capsules into the rectum could be difficult if the capsules are not coated with a 
glidant (Hannula et al., 1986; Eerikäinen et al., 1996). 
In 1983, Takagishi and co-workers patented a hard two-piece capsule for rectal 
application which was made of enterosoluble materials selected from the group 
consisting of mixed esters of an alkylcellulose, hydroxyalkylcellulose or 
hydroxyalkyl alkylcellulose (Pat.U.S. 4,402,692; 4,405,597). These capsules 
could be filled also with aqueous medicines in the form of aqueous solution, 
aqueous suspension or emulsion, which is not possible with hard gelatine 
capsules. However, investigators observed considerable interindividual variation 
in capsule disintegration in the rabbit rectum, and therefore variation in drug 
absorption, when the capsules were filled with aqueous or oily substances. The 
problem was solved by filling the capsules with aqueous liquid that has an 
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osmotic pressure substantially higher than that of the rectal fluid, but not so high 
as to irritate the rectal membrane. The investigators evaluated these enterosoluble 
capsules only with test animals (e.g. rabbits) and no further studies conducted 
with healthy volunteers can be found in the literature.  
The first hard gelatine capsule for rectal administration was patented in 1984 
for indomethacin (Pat.DE 3,241,263 A1). In addition, the feasibility of hard 
gelatine capsules for rectal administration has been evaluated in humans with 
paracetamol (Hagenlocher et al., 1987), doxepin and carbamazepine (Storey and 
Trumble, 1992), ibuprofen (Eerikäinen et al., 1996; Leino et al., 1997; 1999) and 
metoclopramide hydrochloride (Leino et al., 2003). Hagenlocher and co-workers 
(1987) compared the bioavailability of paracetamol from hard gelatine capsules 
filled with amphiphilic (polyoxyethylated fats) or lipophilic (hard fat/oil mixture) 
excipients with a hard fat suppository and an aqueous suspension microenema, 
using an oral solution as a control formulation. The results indicated that the 
bioavailability of the model drug from both capsule formulations was comparable 
with that from the suppository and the microenema. It was also concluded that it 
is possible to achieve fast and more homogeneous in vivo dissolution of 
paracetamol from amphiphilic capsule formulations than from lipophilic capsules 
and suppositories. Hardy and co-workers (1987) further evaluated the mechanism 
of the increased absorption from the amphiphilic capsules by imaging the 
spreading of the capsule contents (Witepsol and Labrafil) in the human rectum 
with gamma scintigraphy. The base and the suspended non-absorbing agent, a 
cation exchange resin representing the drug substance, were labeled separately in 
order to evaluate the relative movements of the base and the “drug”. Generally, 
the spreading of the bases was not great and there were no differences between the 
two bases. Mostly the base and the resin remained together in the rectum. On the 
other hand, if the capsule contents were spread, it was related more to movement 
of the base than the suspended resin. Therefore, differences in the absorption of 
paracetamol from different bases in the study of Hagenlocher and co-workers 
(1987) probably cannot be explained by the differences in spreading. 
Storey and Trumble (1992) reported the use of doxepin and carbamazepine 
capsules as rectal dosage forms for patients suffering from cancer. The patients 
were not able to take oral medication and there were no injections available. Hard 
gelatine capsules containing powdery drugs turned out to be clinically useful and 
there was no need to use long and expensive processes for making suppositories 
of these drugs substances.  
Eerikäinen and co-workers (1996) investigated the bioavailability of ibuprofen 
from rectally administered hard gelatine capsules containing lactose or HPMC 
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K15M (15,000 mPa⋅s) as a diluent, using oral capsules containing only ibuprofen 
as a reference. They also evaluated whether the coating of the capsules and 
training in their administration beforehand could affect the rectal bioavailability. 
The results showed that dipping the capsules into liquid paraffin just before 
administration and training in administration beforehand significantly improved 
the bioavailability of ibuprofen from rectal capsules. The amount of ibuprofen 
absorbed from the orally administered capsules and from the rectally administered 
lactose-based capsules was equal and the capsules could be regarded as equivalent 
with respect to the bioavailability (AUC). However, the rate of absorption 
evaluated from Cmax and tmax values was significantly lower for the rectal than for 
the oral capsules and the rectal capsules exhibited a lag time of about 30 min in 
the commencement of drug absorption. The capsules containing HPMC K15M as 
a diluent behaved as prolonged-release formulations, but the bioavailable amount 
of ibuprofen was decreased significantly and the capsules were considered to be 
unsuitable for rectal administration.  
Leino and co-workers (1997) continued to develop rectal prolonged-release 
ibuprofen formulations from hard gelatine capsules by using the lower viscosity 
grades of HPMC, i.e. HPMC K100 (100 mPa⋅s) or HPMC K4M (4000 mPa⋅s).  
There were no differences in the pharmacokinetic parameters between the two 
formulations. When these capsules were compared to lactose-based capsules, a 
clear retardation of drug absorption was observed and adequate prolonged release 
was achieved at least with HPMC K100-based capsules. Also the use of 
polycarbophil in rectal capsules was evaluated. When the diluent consisted of 5% 
polycarbophil and 95% lactose, sufficiently prolonged release of ibuprofen was 
observed. Thus, hard gelatine capsules are useful also as prolonged-release 
formulations with proper diluents.  
In the next study of Leino and co-workers (1999) the effect of the number of 
rectal hard gelatine capsules on the bioavailability of ibuprofen was assessed. The 
amount of ibuprofen was 400 mg and it was administered either in two size 1 
capsules (200 mg per capsule) or in one size 00 capsule. The bioavailability of 
ibuprofen was significantly greater from the two small capsules than from the one 
big capsule, which was supposed to be due to wider spreading to the absorbing 
mucosa of the rectum by the two small capsules. They also studied the effect of 
sodium phosphates on the bioavailability of ibuprofen from rectal hard gelatine 
capsules compared with a commercial suppository and soft gelatine capsule. 
Ibuprofen is a weak acid, which is poorly soluble in water in an acidic 
environment. With a formulation containing disodium hydrogen phosphate and 
sodium dihydrogen phosphate in a ratio of 1/14 (the same as in the Ph.Eur. buffer 
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solution pH 7.5) it was possible to obtain better absorption of ibuprofen than from 
capsules containing only lactose as a diluent. This was most likely due to better 
dissolution of ibuprofen in the rectum, since the pH of the microclimate was 
probably increased by the presence of sodium phosphates. The bioavailability of 
ibuprofen from hard gelatine capsules containing sodium phosphates did not differ 
significantly from the suppositories or the soft gelatine capsules. In addition, the 
interindividual variation was lower with the hard gelatine capsules. Therefore, it 
was concluded that hard gelatine capsules are a notable dosage form for rectal 
administration. 
In order to clarify the effect of the physicochemical properties of the model 
drug on the rectal bioavailability from hard gelatine capsules, Leino and co-
workers (2003) studied the bioavailability of metoclopramide hydrochloride from 
capsules corresponding to those used in the studies conducted with ibuprofen 
(Leino et al., 1999). Unlike ibuprofen, metoclopramide hydrochloride is a weak 
base and readily soluble in water and physiological fluids. Two capsule 
formulations were studied: an immediate-release lactose-based capsule and a 
prolonged-release capsule containing diluents consisting of 5% polycarbophil and 
95% lactose. A commercial metoclopramide suppository was used as a reference. 
The results showed that the bioavailability (AUC) and the rate of absorption (MRT 
and Cmax/AUC) of metoclopramide were similar from the lactose-based capsules 
and from the suppositories. The lag time (tlag) and time for maximum 
concentration (tmax) values were, however, significantly greater for the capsules 
than for the suppositories. Evidently, the differences in the tmax values could be 
explained by the differences in the tlag values. Similar tlag values were also found 
for ibuprofen (Leino et al., 1999), indicating that the time lag at the 
commencement of drug absorption was caused by the disintegration and 
dissolution properties of the capsule shell rather than the solubility of the model 
drug. The drug release from capsules containing polycarbophil was adequately 
prolonged when compared with lactose-based capsules and suppositories. The 
results obtained from corresponding prolonged-release ibuprofen capsules (Leino 
et al., 1999) were quite similar and it was concluded that the solubility of the 
model drug is not very prominent in the assessment of the biopharmaceutical 
characteristics of rectally administered hard gelatine capsule formulations. 
The studies of Eerikäinen and co-workers (1996) and Leino and co-workers 
(1997; 1999) were conducted in the same laboratory as the studies presented in 
this thesis, and they explained the idea of studying rectal administration of the 
HPMC capsules. 
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3. Aims of the study 
As was pointed out in the Introduction (Section 1) and Review of literature 
(Section 2) there is a real need for both in vitro and in vivo scientific evaluation in 
order to determine whether the novel HPMC capsule and the classic hard gelatine 
capsule are interchangeable in the development and clinical use of different types 
of capsule formulations. 
 
The specific aims of the studies were: 
 
• To investigate whether the change of capsule shell material causes any 
changes in the pharmaceutical characteristics of the capsule formulations. 
• To investigate whether the change of capsule shell material causes any 
changes in the bioavailability parameters of the model drugs (ibuprofen and 
metoclopramide hydrochloride). 
• To investigate whether there are equal possibilities for both capsule shell types 
to develop sustained-release formulations utilising HPMC powders of 
different viscosity grades as diluents.  
• To investigate the possible effect of route of administration (oral or rectal) on 
the bioavailability of the model drugs from different capsule formulations. 
• To investigate the possible effect of the chemical nature and water solubility 
of the model drugs on the in vitro and in vivo behaviour of the two capsule 
shell types. 
• To investigate in vitro whether there are any differences between the two 
capsule shell types in their tendency to adhere to isolated porcine oesophagus.  
• To investigate, by means of gamma scintigraphic investigations, the fate 
(movement and disintegration) of orally administered HPMC capsules 
containing different grades of HPMC powder in the human gastrointestinal 
tract.  
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4. Materials and methods 
4.1. Model drugs 
4.1.1. Ibuprofen 
Ibuprofen, 2-(4-isobutylphenyl) propionic acid (Ph.Eur.), was chosen as a model 
drug (I and II), because it is absorbed throughout the GI tract (Parr et al., 1987; 
van Hoogdalem et al., 1991b). Ibuprofen is practically insoluble in acidic aqueous 
solutions (pKa 5.3, Mw 206.3 g mol-1), and therefore it was regarded as 
representative of drugs that are only sparingly soluble in water (Herzfeldt and 
Kümmel, 1983).  
As a non-steroidal anti-inflammatory drug (NSAID), ibuprofen is used for the 
treatment of acute and chronic pain, e.g. dysmenorrhoea and rheumatic diseases, 
as single doses of 200 to 800 mg three to four times a day (Martindale, 1993). The 
maximum dose per day is 3200 mg. A therapeutic plasma drug concentration of 
ibuprofen is from 10 to 50 mg/l, and a concentration of >100 mg/l is toxic 
(Davies, 1998). Following administration of single doses of immediate-release 
preparations, the peak plasma drug concentration is observed within 3 h post-
dose. The elimination half-life (t1/2) is about 2 h. Most of the drug is metabolised 
to at least two metabolites and only less than 1% is excreted unchanged in urine 
(Mills et al., 1973).  
4.1.2. Metoclopramide hydrochloride 
Metoclopramide, 4-amino-5-chloro-2-methoxy-N-(2-diethylaminoethyl) benza-
mide (BP), as the hydrochloride, was chosen as another model drug (III). 
Metoclopramide hydrochloride is a weak base, which is freely soluble in water 
throughout the physiological pH range (pKa 0.6 and 9.6, Mw 354.3 g mol-1) 
(Martindale, 1993; USPDI, 1998). Thus, it was regarded as representative of 
freely water-soluble drugs.  
Metoclopramide is a central dopaminergic antagonist and it is used for the 
treatment of nausea, vomiting and various gut motility disorders (Martindale, 
1993; USPDI, 1998). A therapeutic dose for both oral and rectal administration is 
generally 10 to 20 mg three to four times a day (USPDI, 1998). There is fairly 
little evidence on the relationship between plasma drug concentrations and either 
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the efficacy of metoclopramide or the incidence of adverse effects (Bateman et al., 
1979; Campbell and Bateman, 1992). However, it has been reported that central 
nervous system side effects of metoclopramide are likely to occur when the 
concentration in plasma exceeds 100 ng/ml (Bateman et al., 1979). 
Metoclopramide is absorbed sufficiently and rapidly throughout the 
gastrointestinal tract, but oral and rectal systemic bioavailability has been reported 
as variable, about 32-97% and 53-100%, respectively (Bateman et al., 1980; 
Block et al., 1981; Ross-Lee et al., 1981; Hellstern et al., 1987; Vergin et al., 
1990). The great inter-individual variation and low bioavailability of 
metoclopramide have been shown to be caused by first-pass metabolism, which 
reduces the amount of drug available to the systemic circulation (Ross-Lee et al., 
1981). The peak concentration for immediate-release oral formulations is reached 
about 1 to 2 h after administration (USPDI, 1998; Bateman, 1983). The 
predominant elimination route of metoclopramide is urinary excretion and the 
elimination half-life (t1/2) in healthy subjects is about 3 to 5 h (Bateman et al., 
1980; Wright et al, 1988).  
4.2. Additives 
4.2.1. Hydroxypropyl methylcellulose 
Three grades of hydroxypropyl methylcellulose type 2208 having 19-24% 
methoxy and 4-12% hydroxypropoxy content (Ph.Eur.) (Methocel, Dow 
Chemicals, Great Britain) were used in the development of prolonged-release 
formulations: HPMC K100 (II-IV), HPMC K4M (II-IV) and HPMC K15M (II). 
The nominal viscosities of the HPMCs (measured as a 2% aqueous solution at 
20°C) are 100, 4000 and 15,000 mPa⋅s, respectively.  
4.2.2. Other additives 
Lactose monohydrate (Ph.Eur.) (Der Melkindrustrie, Veghel, The Netherlands) 
was used as a diluent in the immediate-release formulations (I and III). Hard fat 
(Ph.Eur.) (Witepsol W45, mp 35°C) was used as a coating for the rectal capsules 
(I-III). Natural abundance samarium oxide (Sm2O3, purity 99.9%, Aldrich, USA) 
was used for radiolabelling capsules in the gamma scintigraphic study (IV).  
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4.3. Capsule preparation and composition 
Hard size 0 HPMC (Shionogi Qualicaps S.A, Spain) and gelatine (Coni-Snap, 
Capsugel, Belgium) capsules were used in the formulations. All capsules were 
filled manually using a Feton apparatus (Feton International, Belgium). The 
necessary amount of ibuprofen (I and II), metoclopramide hydrochloride (III) or 
samarium oxide (IV) was weighed out into a measuring cylinder and lactose (I 
and III) or hydroxypropyl methylcellulose (II-IV) was added so as to obtain 
sufficient material for a batch of 100 capsules (68 ml). The powders were mixed 
manually, after which the capsule bodies were filled. The quality of the batches 
was tested according to Ph.Eur. 3th Ed. (mass and content uniformity of single-
dose preparations and disintegration of capsules). The capsules for rectal 
administration were coated by dipping them into melted hard fat using tweezers. 
The compositions and routes of administration of the capsules are presented in 
Table 4.  
Table 4. Compositions (mg) and routes of administration of the capsule formulations. 
Capsules for rectal administration were coated with hard fat (q.s.).  
Study Capsule Ibuprofen  Metoclopramide  Sm2O3 Lactose HPMC HPMC HPMC Route of  
 material    K100  K4M K15M administration 
    (mg) (mg) (mg) (mg) (mg) (mg) (mg)   
HPMC 200 - - 157 - - - oral 
HPMC 200 - - 152 - - - rectal 
Gelatine  200 - - 171 - - - oral 
I 
Gelatine  200 - - 157 - - - rectal 
HPMC 200 - - - 145 - - oral and rectal 
HPMC 200 - - - - 141 - oral and rectal 
HPMC 200 - - - - - 143 oral and rectal 
Gelatine  200 - - - 141 - - oral and rectal 
Gelatine  200 - - - - 140 - oral and rectal 
II 
Gelatine  200 - - - - - 142 oral and rectal 
HPMC - 10 - 453 - - - oral and rectal 
HPMC - 10 - - 245 - - oral and rectal 
HPMC - 10 - - - 240 - oral 
Gelatine  - 10 - 450 - - - oral and rectal 
Gelatine  - 10 - - 240 - - oral and rectal 
III 
Gelatine  - 10 - - - 235 - oral 
HPMC - - 6 - 260 - - oral IV 
HPMC - - 6 - - 261 - oral 
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4.4. In vitro studies 
4.4.1. Drug release from capsules (I-III) 
The release of ibuprofen and metoclopramide from HPMC and gelatine capsules 
was studied using the basket method described in USP 24. The dissolution 
medium was USP neutral potassium phosphate buffer (I) and USP neutral tribasic 
sodium phosphate buffer (I-III) (900 ml at 37 ± 0.5 °C). The speed of rotation was 
100 min-1 for the metoclopramide capsules (III) and 150 min-1 for the ibuprofen 
capsules (I and II). The dissolution apparatus (Sotax AT 6, Sotax AG, 
Switzerland) was connected to a peristaltic pump (Watson-Marlow 503S, Smith & 
Nephew Watson-Marlow, United Kingdom) and to a flow-through 
spectrophotometer (Ultrospec II, LKB Biochrom Ltd., United Kingdom). The 
absorbance of the dissolution medium in 2 mm flow-through cells was recorded 
automatically at regular intervals. The absorbance measurements were computer-
controlled by tablet dissolution software (TDS, LKB Biochrom Ltd., United 
Kingdom). The amount of ibuprofen and metoclopramide released was measured 
in parallel from six samples. 
The release kinetics of ibuprofen and metoclopramide from capsules diluted 
with HPMC powders of different viscosities (II and III) were evaluated with the 
power-law equation describing fractional release from swellable devices 
(Korsmeyer et al., 1983; Ritger and Peppas, 1987). 
nt kt
M
M
=
∞
 
In this equation, Mt/M∞ is the fractional amount of drug released at time t, k is the 
kinetic constant and n is the release exponent, indicative of the mechanism of 
release. The power-law equation predicts that the fractional release of drug is 
exponentially related to the release time. The exponent n depends on the geometry 
of the device. For Fickian diffusion from swellable spheres and cylinders the 
exponent takes the values n = 0.43 and 0.45, respectively (Ritger and Peppas, 
1987). Greater values of n indicate non-Fickian release, where the drug release 
depends on the ratio between the polymer relaxation rate and the rate of diffusion 
of the drug in gel. A value of n = 1 means that the drug release is independent of 
time, regardless of the geometry. The release kinetics of the model drugs were 
calculated until 80% of the dose was released or to the end of the dissolution test 
if less than 80% was released. 
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4.4.2. Adherence to isolated oesophageal preparation 
(II) 
An isolated porcine oesophagus method was used to determine the tendency of the 
HPMC capsules to stick to the oesophagus compared with corresponding gelatine 
capsules (II). Immediately after slaughter of a male Landrace pig, weight about 
100 kg, the oesophagus was removed and taken to the laboratory in Tyrode’s 
solution. Segments (6-7 cm long) were cut from the oesophagus and mounted in a 
classic organ bath for isolated preparations as described in detail elsewhere 
(Marvola et al., 1982). HPMC and gelatine capsules (n = 10) were filled with 
lactose and placed in the oesophageal preparation for 1.5 min. The force needed to 
detach the product was then measured using a modified prescription balance; the 
force used was taken as a measure of adherence. The statistical evaluation was 
carried out using Student`s t-test. 
4.5. In vivo studies 
4.5.1. Bioavailability studies (I-III) 
Seven groups of 7 to 8 healthy volunteers of both sexes participated in a series of 
randomised, cross-over, single-dose studies carried out in accordance with the 
recommendations of the Declaration of Helsinki (World Medical Assembly, 1964) 
and subsequent amendments. The ages of the subjects ranged from 20 to 32 years 
and their weights from 53 to 88 kg. The subjects were informed about possible 
risks and side effects of the drugs and their written consent to participation was 
obtained. During the study, side effect forms were filled and collected. The Ethics 
Committee of University Pharmacy, Helsinki, accepted the study protocols. The 
National Agency for Medicines (Finland) was duly notified. The experiments 
were carried out in University Pharmacy, Helsinki.   
4.5.1.1. Procedure 
The amount of ibuprofen in studies I and II was 400 mg, since the subjects were 
administered two capsules each containing 200 mg (Table 4). The amount of 
metoclopramide hydrochloride corresponding to metoclopramide was 10 mg and 
the subjects were administered one capsule (III). Orally administered capsules 
were taken with 200 ml of water after the subjects had fasted overnight for at least 
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10 h. Rectally administered capsules were taken after a standard breakfast, which 
was served one hour before the drug insertion to facilitate and enable normal 
bowel movement. A standard lunch was served to all subjects 4 h after drug 
administration. The blood-samples were collected from an antecubital vein at 
intervals. The wash-out period between the administrations of different capsule 
formulations was at least one week. The subjects taking rectal capsules were 
instructed on the correct insertion technique before the bioavailability tests using 
capsules containing only lactose.  
4.5.1.2. Assay methods 
The ibuprofen and metoclopramide concentrations in plasma were determined by 
means of high performance liquid chromatography using a slightly modified 
method of Avgerinos and Hutt (1986) for ibuprofen and Buss and co-workers 
(1990) for metoclopramide. The accuracy and precision of the methods were 
determined as recommended by Shah and co-workers (1992). Both methods 
fulfilled the validation criteria (I, Section 3.3.; II, Section 2.3.5.; III, Section 3.3.).    
4.5.1.3. Data analysis 
 The pharmacokinetic parameters calculated (Siphar, Simed, France) from plasma 
samples were maximum concentration (Cmax), time to peak concentration (tmax), 
absorption time lag (tlag), area under the concentration time curve (AUC), mean 
residence time (MRT) and apparent elimination half-life (t1/2). The rate of 
absorption was evaluated also using the ratio Cmax /AUC. Statistical analyses 
(p<0.05 was considered as statistical significant) were carried out using 
Wilcoxon’s matched-pairs rank test for the tmax values and Student’s paired t-test 
for the other pharmacokinetic parameters. For the AUC values, 90 % confidence 
intervals with logarithmic transformation were also calculated and the gelatine 
capsules were the reference formulations (I and III). 
4.5.2. Gamma scintigraphic studies (IV) 
One group of six healthy male volunteers participated in the gamma scintigraphic 
studies. The ages of the subjects ranged from 19 to 28 years and their weights 
from 65 to 89 kg. Their body mass indices (BMI) varied from 19 to 26 kg m-2. 
Each subject was informed about possible risks and adverse effects of taking the 
study formulations. Written informed consent to participation in the studies had 
been obtained. The investigations were carried out in accordance with the 
  28 
 
International Conference on Harmonization (ICH), Good Clinical Practice 
Guidelines and the Declaration of Helsinki (World Medical Assembly, 1964) and 
subsequent amendments. The National Agency for Medicine (Finland) and the 
Ethics Committee of Helsinki University Central Hospital (HUCH) approved the 
study protocol. The studies were carried out in the Nuclear Medicine Division of 
HUCH, which has a radiation safety licence issued by STUK (Radiation and 
Nuclear Safety Authority of Finland). Safety requirements were set in accordance 
with the guidelines established by STUK. The ALARA (as-low-as-reasonably-
achieveable) principle was observed, and exposure to radiation was minimised in 
every situation. 
4.5.2.1. Procedure 
Each capsule contained 6 mg of 152Sm2O3 (Table 4). The 152Sm was activated in a 
thermal neutron flux to the gamma emitting nuclide 153Sm (t1/2 46.3 h), using a 
250-kW TRIGA Mark II nuclear research reactor (General Atomics, USA) at the 
Technical Research Centre of Finland (VTT). Gamma scintigraphic studies were 
carried out 48 h after neutron activation. This time period allowed decay of 
unwanted radioisotopes, primarily 24Na. The gamma spectra and radioactivity of 
the 153Sm were measured to determine the safety of the formulations. Safety 
requirements were fulfilled for every formulation (IV, Section 2.3.). 
Each study subject received both 153Sm-labelled formulations (Table 4), one at 
a time on two separate visits. A wash-out period of one week between visits 
cleared the radioactivity from the gastrointestinal tract. The formulations were 
administered in a sitting position with 180 ml of water. The subjects remained in a 
sitting position for at least 30 s before lying down under the gamma camera. The 
subjects had fasted overnight for at least 12 h. Except for the first two subjects 
who received extra water (180 ml) 20 min after the administration due to the 
adherence of the capsules to the oesophagus on the first study visit, the subjects 
were not allowed to drink or eat until 4 h after the administration when a standard 
lunch was served. Following administration, anterior and posterior images, each 
of 1 min duration, were recorded continuously for the first 20 min, after which six 
images, each of 1 min duration, were recorded every 30 min for the next 7.5 h by 
means of a dual-head gamma camera (ADAC Forte, ADAC Laboratories, USA). 
During imaging each subject lay supine beneath the gamma camera. At other 
times they could move freely. 
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4.5.2.2. Data analysis 
Sequential computer-generated images were used for each subject and the regions 
of interest (ROI) were drawn to represent the oesophagus and the stomach (of a 
fixed size for paired anterior and posterior images), and counts relating to ROIs 
were calculated using Hermes software (version 3.7, Nuclear Diagnostics, 
Sweden). Geometric means of counts in paired anterior and posterior images were 
used. All counts were corrected for background and decay.  
The gastric residence time and the large intestine arrival time were determined 
as the midpoint of the time interval between the last image of the capsule in the 
previous region and the time of first detection in the new region. The small 
intestine transit time of the capsules was calculated by subtracting the gastric 
residence time from the time at which the capsules were observed to move from 
the ileo-caecal junction to the large bowel.  
The initial capsule disintegration time was defined as the midpoint of the time 
interval between the last image of the capsule with clear outlines and visually 
undetectable spreading of the radioactivity and the time of first detection of 
spreading radiation. The time for capsules to divide was defined as the midpoint 
of the time interval between the last image of the capsule with only one plug 
formation and the time of first detection of the capsule divided into two or three 
pieces. The complete capsule disintegration time was defined as the midpoint of 
the time interval between the last image of the capsule with plug formation and 
the time of first detection of the capsule with no plug formation. The statistical 
analyses were carried out using Wilcoxon´s non-parametric test (p<0.05 was 
considered as statistical significant).  
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5. Results and discussion 
5.1. Biopharmaceutical properties of capsules diluted 
with lactose (I, III) 
5.1.1. In vitro drug release  
The release of ibuprofen from the HPMC and gelatine capsules diluted with 
lactose was first tested in a neutral potassium phosphate buffer, in which the 
release from the HPMC capsules was incomplete and highly variable compared 
with the gelatine capsules (I, Fig. 1). This was probably due to the presence of 
potassium ions in the dissolution media, which could have promoted gelation of 
the carrageenan in the HPMC capsule shells causing the capsule shells to form a 
gel membrane around the filling. Also Ogura and co-workers (1998) noticed this 
phenomenon and they suggested that, since the cation concentration in the gut is 
low, dissolution mediums that do not contain potassium could be used. Therefore, 
the dissolution medium was changed to the neutral tribasic sodium phosphate 
buffer described in the USP for enteric formulations, in which the release of 
ibuprofen from the HPMC capsules was complete and less variable. The same 
dissolution medium was used in the subsequent studies.  
The release of the model drugs, ibuprofen and metoclopramide, from the 
HPMC and gelatine capsules diluted with lactose was fast with 100% of the drug 
dose being released within 15 to 20 min (I, Fig. 2; III, Fig. 1). There were no 
differences between the HPMC and gelatine capsules in the time when 100% of 
the drug dose was released. However, one difference was observed: the release of 
both ibuprofen and metoclopramide from the HPMC capsules started after a lag 
time of about 4 min, whereas the release of the model drugs from the gelatine 
capsules started almost immediately. Since the same phenomenon was detected 
for both drugs, which differ from each other in chemical nature and water 
solubility, it can be suggested that the physicochemical characteristics of the drug 
do not affect the dissolution of the capsule shells when the capsules are diluted 
with lactose. Also Chiwele and co-workers (2000) reported that the disintegration 
of empty HPMC capsule shells at 37°C takes about 4 min, whereas the 
disintegration of empty gelatine capsule shells takes at most 1 min. In addition, 
Wu and co-workers (2003) claimed that the release of an investigational drug, 
BMS-309403, was slower from HPMC capsules than from corresponding gelatine 
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capsules during the first 10 to 20 min. This kind of difference between the two 
capsule shells was not reported by Ogura and co-workers (1998) or Podczeck and 
Jones (2002) when the capsules were filled with a model drug and a diluent. On 
the contrary, Podczeck and Jones (2002) claimed that the release of theophylline 
from the HPMC capsules was faster and greater than from the corresponding 
gelatine capsules when the capsules contained either theophylline only or 
theophylline together with lactose or microfine cellulose (immediate-release 
formulations). It should be noted, however, that they studied only the relative 
amount of drug dissolved after 60 min and the mean dissolution time (MDT), not 
the differences in the dissolution rates between the capsules during the first 10 
min.  
5.1.2. Oral bioavailability 
The mean ibuprofen concentration versus time curves after oral administration of 
the HPMC and gelatine capsules diluted with lactose were virtually identical, and 
there were no statistically significant differences in the bioavailability parameters 
between the two different capsule shell types (I, Fig. 3 and Table II). Similar 
results were obtained also when the model drug was metoclopramide 
hydrochloride (III, Fig. 3 and Table III), but there was one difference in the 
bioavailability parameters: the time to peak concentration (tmax) was significantly 
shorter for the HPMC capsules than for the gelatine capsules. This means that the 
maximum concentration of metoclopramide was reached about 20 min faster with 
the HPMC capsules than with the gelatine capsules. This is not in line with the in 
vitro dissolution studies, where the release of the model drugs from the HPMC 
capsules began more slowly than from the gelatine capsules.  
The HPMC and gelatine capsules containing ibuprofen could also be regarded 
as bioequivalent (mean 1.0; 90% CI 0.90-1.19) (I)i, but not the corresponding 
metoclopramide capsules (mean 1.09; 90% CI 0.85-1.32) (III), probably due to a 
greater variation in the AUC values. The first-pass metabolism of metoclopramide 
in the liver is known to cause extensive inter-individual variation in the 
bioavailability of metoclopramide (Ross-Lee et al., 1981). Therefore, with a 
greater number of subjects (n > 8) it may be possible to obtain the generally used 
90% confidence interval of 0.80-1.25. Nevertheless, the change of capsule shell 
type did not affect the amount of metoclopramide absorbed, since there was no 
statistically significant difference in the AUC values between the capsules. There 
was also evidence that both the HPMC and gelatine capsules containing ibuprofen 
                                                
i
 The reference formulation in Study I was accidentally HPMC capsule, not gelatine capsule as it should have been. 
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may have attached to the oesophagus or the upper parts of the stomach causing 
delayed in vivo disintegration of the capsules in one subject (different subject on 
each occasion) (I, Fig. 4). This finding led to a suspicion that also HPMC capsules 
could have a tendency to attach to the oesophagus or gastrointestinal mucosa, 
which has been recognised as a problem with gelatine capsules (Swisher et al., 
1984), and further investigations concerning the sticking properties of the HPMC 
capsules were needed.  
The overall conclusion from these results was that when the HPMC and 
gelatine capsules are administered orally as immediate-release formulations, the 
capsule shells could be regarded as interchangeable. This is in accordance with 
the studies of Ogura and co-workers (1998) who investigated the oral 
bioavailability of cephalexin from HPMC and gelatine capsules with six healthy 
volunteers. 
5.1.3. Rectal bioavailability 
Several previous studies have demonstrated that following the rectal 
administration of hard gelatine capsules, disintegration of the capsule shell and 
dissolution of powdered drug into the limited amount of fluid available in the 
rectum is a time consuming process, causing time lags of about 30 min in the 
commencement of ibuprofen and metoclopramide absorption (Eerikäinen et al., 
1996; Leino et al., 1997,1999, 2003). Also the studies reported here demonstrate 
that the rectal gelatine capsules containing ibuprofen or metoclopramide 
hydrochloride as the model drugs and lactose as the diluent exhibited time lags of 
about 30 min. However, the rectal HPMC capsules exhibited even greater time 
lags, about 50 min. Consequently, the difference in the tlag values between the 
HPMC and gelatine capsules containing either ibuprofen or metoclopramide 
hydrochloride was statistically significant (I, Table III; III, Table IV). These 
findings are in accordance with the in vitro results, where the disintegration of the 
HPMC capsules was slower than that of the gelatine capsules. Since both 
ibuprofen and metoclopramide exhibited higher tlag values from the HPMC 
capsules than from the gelatine capsules, it can be assumed that the capsule shell 
dissolution properties rather than the physicochemical properties of drugs 
determine the release and absorption from hard rectal capsules. 
The parameter reflecting absorption rate (Cmax/AUC) was significantly higher 
for the HPMC capsules containing ibuprofen than for the corresponding gelatine 
capsules (I, Table III), indicating that after the capsules disintegrated in the 
rectum, the dissolution and subsequent absorption of ibuprofen was faster from 
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the HPMC capsules than from the gelatine capsules. However, this was not seen 
in other parameters reflecting the absorption rate (tmax, Cmax, MRT). On the other 
hand, the great tlag value of the HPMC capsules was not reflected in the tmax value, 
which was on average 3 h for both capsule shell types. This indicates that 
although the disintegration of the HPMC capsules in the rectum may have been 
slower than that of the gelatine capsules, the effect is cancelled by the slightly 
faster absorption of ibuprofen from the HPMC capsules. This may be explained 
by the differences in the dissolution properties of the HPMC and gelatine capsule 
shells that were noted by Podczeck and Jones (2002). They reported that the 
HPMC capsule shells dissolve more evenly than the gelatine capsule shells, 
meaning that the whole powder plug filled in the HPMC capsules may be 
subjected to dissolving fluid simultaneously, whereas the gelatine capsules 
disintegrate first from the shoulders with the other parts following only later.  
Also following rectal administration of the HPMC capsules containing 
metoclopramide hydrochloride, the Cmax/AUC values were significantly higher 
than those for the gelatine capsules (III; Table IV), indicating faster drug 
absorption from the HPMC capsules. However, the difference in the tlag values 
between the two capsule types was so great that it was reflected in the tmax values, 
which were significantly greater for the HPMC capsules than for the gelatine 
capsules. Therefore, the difference in the Cmax/AUC values is of hardly any 
significance in practice for metoclopramide. 
The great variation of the AUC values for both ibuprofen and metoclopramide 
capsules regardless of the capsule shell material may be the reason why the 
rectally administered HPMC and gelatine capsules could not be regarded as 
bioequivalent (mean 1.0, 90% CI 0.57-1.43 for ibuprofen (I)ii and mean 0.90, 90% 
CI 0.72-1.08 for metoclopramide (III)). However, by increasing the number of 
subjects it may be possible to decrease the variation of the AUC values and, 
consequently, reach the 90% confidence interval of 0.80-1.25. Nevertheless, the 
change in the capsule shell material did not affect statistically significantly the 
bioavailability (AUC) of the model drugs and the variation in the 
biopharmaceutical parameters was similar for both capsule shell types. Therefore, 
the HPMC capsules could be regarded as a noteworthy alternative to the gelatine 
capsules when rapid drug action is not required. When there is need for quick 
onset of action after rectal administration, a rectal enema should be considered as 
the first choice. 
When the administration route is evaluated, it can be seen that the Cmax values 
of ibuprofen after rectal administration of the capsules were only half those 
                                                
ii
 
The reference formulation in Study I was accidentally HPMC capsule, not gelatine capsule as it should have been.
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obtained with the corresponding oral capsules (I, Tables II and III). In addition, 
when the AUC values are compared between the rectal and oral capsules, the 
mean rectal bioavailability of ibuprofen was 75-85% of that recorded after oral 
administration. This is not in accordance with previous studies, where similar 
AUC values have been obtained for rectally and orally administered gelatine 
capsules containing ibuprofen and lactose (Eerikäinen et al., 1996). The reason for 
the decreased absorption of ibuprofen from rectal capsules in the present study 
could be due to poor technique for insertion of the capsules into the rectum. It has 
been demonstrated that training in administration beforehand and the use of a 
glidant to facilitate insertion increase the bioavailability of ibuprofen from rectal 
hard gelatine capsules (Eerikäinen et al., 1996). In the study reported here, the 
subjects were trained in administration and the capsules were coated with hard fat. 
Nevertheless, one of the subjects receiving gelatine capsules containing ibuprofen 
failed in insertion and no drug was recovered during the 12-hour test period. It 
was obvious that the capsules had stuck to the anus and had not passed the 
sphincters, making absorption impossible. This subject was excluded from the 
study. Also the degree of variation in the concentration versus time curves for the 
rectally administered ibuprofen capsules was clearly greater than for the 
corresponding orally administered capsules (I, Figs. 4 and 6). Great variation in 
the absorption of ibuprofen from rectal hard gelatine capsules was also reported in 
the previous studies (Eerikäinen et al., 1996; Leino et al., 1997, 1999). In 
conclusion, the rectal hard capsules made of either HPMC or gelatine could be of 
value for rectal administration, but attention must be paid to the insertion 
technique.  
Unlike rectal administration of ibuprofen, rectal administration of 
metoclopramide hydrochloride turned out to be better than oral administration: 
the Cmax and AUC values were greater for the rectal capsules than for the 
corresponding oral capsules (III, Tables III and IV). This indicates that the rectally 
administered metoclopramide at least partially avoided first-pass metabolism. The 
inter-individual variation was, however, slightly greater for the rectal capsules 
than for the oral capsules (III, Figs. 4 and 6), indicating that rectal administration 
did not reduce the variation even though first-pass elimination may have been 
partially avoided. Nevertheless, due to the better absorption, hard capsules can be 
regarded as valuable for rectal metoclopramide formulations if rapid onset of 
action is not needed. 
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5.2. Biopharmaceutical properties of capsules diluted 
with HPMC powder (II, III) 
5.2.1. In vitro drug release  
The capsule shell material did not seem to have any marked effect on the release 
profile of ibuprofen from capsules diluted with the HPMC powder and the 
release curves obtained from the HPMC and gelatine capsules containing the 
same polymer were almost completely overlapping (II, Fig. 2). However, the 
release constants, K, were slightly smaller for the HPMC capsules than for the 
corresponding gelatine capsules, especially when the capsules were diluted with 
the HPMC K100 powder (II, Table 2). This indicates slightly slower dissolution 
of ibuprofen from the HPMC capsules. The sampling interval was 15 min and, 
when the first sample which was obtained 15 min after starting the test was 
examined, the slower disintegration of the HPMC capsule shells noted with the 
capsules diluted with lactose (Section 5.1.1.) was no longer detectable.  
The viscosity grade of the HPMC powder used as the diluent had a clear effect 
on the release rate of ibuprofen. Both HPMC and gelatine capsules containing the 
lower viscosity grade, HPMC K100, had K values which were almost double 
those for the capsules containing the higher viscosity grades, HPMC K4M or 
K15M (II, Table 2). The release rate of ibuprofen was not further decreased when 
the HPMC polymer was changed from K4M to K15M.  
The capsule shell material did not affect the release mechanism of ibuprofen, 
whereas the viscosity grade of the HPMC polymer had an evident effect. The 
release of ibuprofen from HPMC and gelatine capsules diluted with HPMC K100 
powder followed zero-order kinetics quite well with values of the exponent n 
close to 1 (II, Table 2). This may indicate that the drug release from these 
capsules was independent of time and was mainly controlled by the erosion rate of 
the HPMC polymer. The values of the exponent n for capsules containing HPMC 
K4M or K15M powder (0.64-0.67) indicated non-Fickian release kinetics, i.e. the 
release mechanism of ibuprofen may have been a combination of the polymer 
relaxation rate and the rate of diffusion through the gel layer. When the results 
presented here are compared with the results obtained with ibuprofen capsules 
diluted with lactose, it can be seen that all HPMC polymers used as the diluent 
clearly prolonged the release of ibuprofen (I, Fig. 2; II, Fig. 2).  
When the model drug was metoclopramide hydrochloride and the capsules 
were diluted with HPMC K100 or K4M powder, the capsule shell material had a 
slight effect on the release of metoclopramide. The release rate constant K was 
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somewhat higher for the HPMC capsules than for the corresponding gelatine 
capsules (III, Table II), indicating that the release of metoclopramide was slightly 
faster from the HPMC capsules than from the corresponding gelatine capsules, 
which can be seen also from the release curves (III, Fig. 2). This is in accordance 
with the studies of Podczeck and Jones (2002), but not with the studies reported 
here conducted with ibuprofen. Thus, the chemical nature and water-solubility of 
the model drug had an effect on the release from the two different capsule shells 
when the capsules were diluted with the HPMC powder. This slight difference 
between the model drugs was not seen when the capsules were diluted with 
lactose (Section 5.1.1.). 
As was seen with the ibuprofen capsules, also the release rate of 
metoclopramide was decreased when the HPMC polymer was changed from the 
lower viscosity grade, K100, to the higher viscosity grade, K4M (III, Table II). 
The release mechanisms of metoclopramide from both HPMC and gelatine 
capsules diluted with HPMC K100 was non-Fickian (values of exponent n 0.7), 
whereas the release of metoclopramide from capsules containing the higher 
viscosity grade was closer to square root of time kinetics (values of exponent n 
close to 0.5). All the capsules behaved as prolonged-release formulations when 
compared with the capsules diluted with lactose (III, Fig. 1 and 2). 
The release behaviour of drugs from swellable polymeric systems is often 
described in terms of non-Fickian diffusion (Peppas, 1985). However, some 
studies have shown that the water-solubility of the drug may affect the release 
kinetics from matrix tablets prepared with various viscosity grades of HPMC type 
2208, i.e. the release mechanism of freely water-soluble drugs has been reported 
to be non-Fickian (Ford et al., 1987; Catellani et al., 1988; Colombo et al., 1990; 
Ranga Rao et al., 1990; Colombo et al., 1992; Peppas and Colombo, 1997; 
Colombo et al., 1999; Ferrero Rodriguez et al., 2000), whereas the release 
mechanism of poorly water-soluble drugs has been reported to obey nearly zero-
order release (Ford et al., 1987; Ranga Rao et al., 1990) when the kinetics of the 
model drugs have been evaluated by using the same power law equation utilised 
here. Also in the studies reported here, the release mechanism of the freely water-
soluble metoclopramide hydrochloride from the capsules containing HPMC K100 
as the diluent was non-Fickian, whereas the release of the poorly water-soluble 
ibuprofen from the corresponding capsules followed zero-order kinetics quite 
well. However, from capsules containing the higher viscosity grades of the HPMC 
polymers both model drugs obeyed non-Fickian release, although the release of 
metoclopramide tended slightly more to Fickian diffusion. It should be noted, 
though, that the compositions of the ibuprofen and metoclopramide capsules were 
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different, and they could be compared directly only if the drug/HPMC ratio was 
the same for both formulations. Other studies utilising the power law to evaluate 
the release kinetics of drugs from capsule matrices made of HPMC polymers 
cannot be found in the literature. 
5.2.2. Oral bioavailability 
5.2.2.1. Effect of capsule shell material 
When the model drug was ibuprofen, there was only one difference between the 
capsules diluted with the HPMC powders and differing from each other in the 
capsule shell material. The tmax value of the HPMC capsules containing HPMC 
K100 as the diluent was significantly higher than that of the corresponding 
gelatine capsules (II, Table 3). In other words, the maximum drug concentration 
in plasma was reached on average an hour later from the HPMC capsules than 
from the gelatine capsules diluted with HPMC K100. The in vitro dissolution test 
gave an implication that the release of ibuprofen would be slightly slower from 
the HPMC capsules than from the gelatine capsules when the diluent was HPMC 
K100 powder. Nevertheless, there were no significant differences in any other 
pharmacokinetic parameters between the two formulations diluted with the 
HPMC K100 powder. The other formulations containing HPMC K4M or K15M 
powder as the diluent and differing from each other in the capsule shell material 
did not have statistically significant differences in the pharmacokinetic parameters 
(II, Table 3). In addition, the interindividual variation in drug concentration versus 
time curves was quite similar between the HPMC capsules and the corresponding 
gelatine capsules (II, Fig. 4).  
When the model drug was metoclopramide hydrochloride, there were no 
statistically significant differences in any bioavailability parameters between the 
formulations differing from each other in the capsule shell material, and also the 
concentration versus time curves were quite similar (III, Table V and Fig. 7). 
Thus, the slightly faster drug release from the HPMC capsules observed in vitro 
was not reflected in vivo. The interindividual variation in the concentration versus 
time curves was slightly greater for the HPMC capsules than for the 
corresponding gelatine capsules (III, Fig. 8). However, this may be due to the 
differences in the first-pass metabolism of metoclopramide rather than to the 
capsule shell material, since there were no differences in the variation between the 
orally administered metoclopramide capsules diluted with lactose or the ibuprofen 
capsules diluted with lactose or HPMC polymers.  
  38 
 
The overall conclusion about the interchangeability of the two capsule shell 
materials is that, from a biopharmaceutical point of view, the HPMC capsules 
could be regarded as a noteworthy alternative to gelatine capsules also when the 
capsules contain either ibuprofen or metoclopramide as the model drug and 
HPMC polymers of different viscosities as the diluent.  
5.2.2.2. Effect of diluent   
The results obtained for the orally administered ibuprofen capsules diluted with 
either lactose (I) or HPMC powders (II) are gathered in Table 5. As can be seen 
from Table 5, the replacement of lactose with the HPMC powder prolonged the 
release and subsequent absorption of ibuprofen. Following oral administration of 
the capsules diluted with the HPMC powder, the tmax and MRT values were 
increased and the Cmax and Cmax/AUC values were decreased, but t1/2 remained 
almost unaffected, when compared with the capsules diluted with lactose. Also 
the tlag values were increased from about 10 to 30 min, indicating fast hydration of 
the HPMC powder used as the diluent, which inhibits premature drug release. 
Prolonged release of drugs is beneficial if, e.g. the elimination half-life of a 
drug is short and there is a need for decreased fluctuation and constant 
concentration of the drug in plasma over a long period. By prolonging the release 
of drug from a delivery device, it is possible to achieve a situation where the drug 
release in vivo is the rate-limiting step in drug kinetics. In other words, the very 
slow drug release and consequently slow absorption limit the rate of elimination 
of the drug and extend the apparent half-life allowing a longer interval between 
doses. Ibuprofen is a good candidate for prolonged-release formulations, since its 
elimination half-life is short, about 2 h. However, in this study the ibuprofen 
capsules diluted with HPMC polymers behaved as slow-release formulations 
rather than as extended-release formulations, since the elimination half-life (t1/2) 
of ibuprofen was not extended (Table 5).   
It is important to note that although the absorption of ibuprofen was slower 
from the capsules diluted with the HPMC polymer, there was no loss in the 
bioavailable amount (AUC) compared with the lactose-based capsules (Table 5). 
Also the viscosity grade of the HPMC polymer used as the diluent did not affect 
the amount of ibuprofen absorbed from the capsules, since there were no 
statistically significant differences in the AUC values between the different 
formulations (Table 5). However, the viscosity grade of the HPMC powder 
affected the absorption rate of ibuprofen, which was greater from the HPMC 
K100-based capsules than from the HPMC K4M- and K15M-based capsules. 
When the capsule shell was HPMC, the Cmax and Cmax/AUC values were 
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significantly greater and the MRT values were significantly smaller for the HPMC 
K100-based capsules than for the HPMC K4M- and K15M-based capsules (Table 
5). When the shell material was gelatine, the Cmax and Cmax/AUC values were 
significantly greater and the tmax values were significantly smaller for the HPMC 
K100-based capsules than for the HPMC K4M- and K15M-based capsules. No 
changes in the pharmacokinetic parameters occurred when the HPMC polymer 
was changed from K4M to K15M. All these in vivo findings with the different 
viscosity grades of the HPMC polymers used as the diluent are in line with the in 
vitro dissolution results. Similar results were also obtained in previous in vivo 
studies conducted with orally administered gelatine capsules containing ibuprofen 
and HPMC polymers of different viscosities (Ojantakanen et al., 1993). 
Table 5. Pharmacokinetic parameters of ibuprofen (single dose of 2x200 mg) following 
oral administration of capsules containing lactose (I) or HPMC polymers of different 
viscosity grades (II) (n=8, mean ± S.D.). Parameters between the lactose and HPMC 
powder-based capsules were not tested statistically since the capsules were taken by two 
different subject groups.   
Diluent Capsule AUC (mgh/l) 
Cmax   
(mg/l) 
tmax          
(h) 
MRT      
(h) 
Cmax/AUC 
(h-1) 
tlag         
(h) 
t1/2        
(h) 
HPMC 110 ± 18 39 ± 11 1.5 ± 1.0 2.7 ± 1.4 0.35 ± 0.068 0.11 ± 0.11 2.4 ± 2.5 
Lactose 
gelatine 110 ± 30 40 ± 7.0 1.2 ± 0.75 2.4 ± 0.79 0.38 ± 0.085 0.072 ± 0.17 2.0 ± 1.3 
HPMCa 130 ± 48 26 ± 9.6 3.3 ± 0.46 3.4 ± 0.65 0.20 ± 0.042 0.73 ± 0.46 2.4 ± 2.0 HPMC 
K100 gelatineb 120 ± 33 25 ± 7.2 2.2 ± 0.53 4.1 ± 2.5 0.22 ± 0.051 0.36 ± 0.30 2.6 ± 2.2 
HPMCc 110 ± 29 14 ± 4.4 3.2 ± 1.0 4.9 ± 1.4 0.12 ± 0.032 0.53 ± 0.51 2.5 ± 1.6 HPMC 
K4M gelatined 120 ± 30 16 ± 3.9 3.4 ± 0.74 4.7 ± 0.83 0.14 ± 0.024 0.56 ± 0.40 2.2 ± 1.5 
HPMCe 100 ± 42 13 ± 5.3 4.3 ± 1.9 5.4 ± 1.5 0.12 ± 0.010 0.75 ± 0.55 2.9 ± 1.9 HPMC 
K15M gelatinef 120 ± 25 14 ± 3.6 4.3 ± 1.2 6.3 ± 3.2 0.12 ± 0.014 0.63 ± 0.47 3.9 ± 2.5 
Statistical significance       
a/c  NS p<0.01 NS p<0.05 p<0.01 NS NS 
a/e  NS p<0.01 NS p<0.05 p<0.01 NS NS 
c/e  NS NS NS NS NS NS NS 
b/d  NS p<0.01 p<0.05 NS p<0.01 NS NS 
b/f  NS p<0.01 p<0.01 NS p<0.01 NS NS 
d/f   NS NS NS NS NS NS NS 
NS = not significant   
 
Since there were no differences in the biopharmaceutical parameters of ibuprofen 
between the capsules containing the two higher viscosity grades of HPMC, the 
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HPMC K15M polymer was excluded from the next study conducted with the 
other model drug, metoclopramide hydrochloride, and only HPMC K100 and 
K4M polymers were evaluated as the diluents. Metoclopramide is also a good 
candidate for prolonged-release formulations, since its elimination half-life is only 
about 3 to 5 h (Bateman et al., 1980). In addition, fluctuation in plasma 
concentration, with high concentration peaks causing central nervous system 
effects, is common for metoclopramide in long-term therapy (Becket et al., 1987), 
and could be avoided by utilising prolonged-release formulations.  
The results obtained for the orally administered metoclopramide hydrochloride 
capsules diluted with either lactose or HPMC powder (III) are gathered in Table 6.  
Table 6iii. Pharmacokinetic parameters of metoclopramide following oral administration 
of capsules containing lactose or HPMC polymers of different viscosity grades (III) (n=8 
for the lactose-based capsules and n=7 for the HPMC powder-based capsules, mean ±
 
S.D.). Parameters between the lactose- and HPMC powder-based capsules were not 
tested statistically, since there were two different subject groups taking the capsules. 
Diluent Capsule AUC (ngh/ml) 
Cmax   
(ng/ml) 
tmax          
(h) 
MRT      
(h) 
Cmax/AUC  
(h-1) 
tlag        
(h) 
t1/2        
(h) 
HPMC 162 ± 72 31 ± 14 1.3 ± 0.46 4.8 ± 1.9 0.20 ± 0.030 0.27 ± 0.25 3.4 ± 1.5 
Lactose 
gelatine 154 ± 61 30 ± 11 1.7 ± 0.65 4.1 ± 2.1 0.20 ± 0.032 0.16 ± 0.17 2.7 ± 1.7 
HPMCa 267 ± 76 29 ± 9.9 4.2 ± 3.6 6.7 ± 2.0 0.11 ± 0.015 0.79 ± 1.1 4.1 ± 2.2 
 HPMC 
K100 gelatineb 242 ± 73 26 ± 6.0 3.4 ± 0.54 7.9 ± 2.4 0.11 ± 0.028 0.79 ± 0.50 5.4 ± 2.5 
HPMCc 215 ± 91 19 ± 6.5 4.7 ± 1.3 7.2 ± 2.8 0.10 ± 0.030 0.91 ± 0.77 4.9 ± 2.5 HPMC 
K4M gelatined 245 ± 70 22 ± 6.8 5.4 ± 1.5 8.1 ± 2.5 0.090 ± 0.017 0.96 ± 0.51 6.9 ± 4.2 
Statistical significance       
a/c  NS p<0.01 NS NS NS NS NS 
b/d   NS NS p<0.01 NS NS NS NS 
NS = not significant   
 
It is quite remarkable that although the release of metoclopramide from the 
capsules diluted with the HPMC K100 powder was prolonged in terms of 
increased tmax and MRT values and decreased Cmax/AUC values, the AUC values 
were greater and the Cmax values were almost unaffected when compared with the 
capsules diluted with lactose (Table 6). The release of metoclopramide from the 
HPMC K4M-based capsules was similarly prolonged and the AUC values were 
greater than those for the lactose-based capsules, but the Cmax values were smaller. 
                                                
iii
 
Misprints in the Study III, Table V: the tmax value for the H4Moral capsules should be 4.71 h, the dimension of the AUC 
and Cmax values should be ngh/ml and ng/ml, respectively, and the AUC values were calculated from 0 to 24 h. 
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The t1/2 values for the HPMC powder-based capsules were also slightly greater 
than those for the lactose-based capsules, but not so much so that the capsules 
could be regarded as extended-release formulations. However, since the lactose-
based and the HPMC powder-based capsules were taken by two different subject 
groups and the inter-individual variation is known to be great in metoclopramide 
medication (Bateman, 1983), it would be advisable to confirm these results by a 
study conducted with a single subject group. 
Changing the HPMC viscosity grade from K100 to K4M had some significant 
effects on the absorption rate of metoclopramide. When the capsule shell material 
was HPMC, Cmax was significantly smaller for the HPMC K4M-based capsules 
than for the HPMC K100-based capsules (Table 6). When the shell material was 
gelatine, tmax was reached significantly later with the HPMC K4M-based capsules 
than with the HPMC K100-based capsules. The viscosity grade of the HPMC 
powder did not affect the bioavailability of metoclopramide, since there were no 
statistically significant differences in the AUC values. This is in accordance with 
the results obtained with ibuprofen. 
In conclusion, the studies conducted with the capsules diluted with the HPMC 
powders of different viscosity grades demonstrate that it is possible to achieve 
prolonged-release capsule formulations for oral administration easily and 
economically by filling the capsules with hydrophilic, swellable polymers. 
However, some optimisation of the formulations is needed. For example, the ratio 
of the model drugs and the HPMC polymer should be re-evaluated in order to 
achieve extended-release capsule formulations and thus a longer dose interval. 
5.2.3. Rectal bioavailability 
5.2.3.1. Effect of capsule shell material 
When the rectal absorption of ibuprofen from the capsules diluted with the 
HPMC powders (K100, K4M or K15M) is examined, it can be seen that the 
capsule shell material did not have any statistically significant effect on the 
biopharmaceutical parameters of the capsules (II, Table 4). Even though the tlag 
values of the HPMC capsules were on average 20 min longer than those for the 
corresponding gelatine capsules, the differences were not statistically significant. 
This is probably due to the wide variation in the tlag values, especially for the 
gelatine capsules (II, Table 4). After rectal administration of ibuprofen capsules 
diluted with lactose, the same difference in the tlag values (about 20 min) between 
the two capsule shell types was statistically significant (I, table III). The greater 
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tlag values of the HPMC capsules diluted with HPMC powder probably have no 
importance in practice, since the capsules are intended for prolonged-release 
formulations. Therefore, the two capsule shell materials can again be regarded as 
interchangeable for rectal ibuprofen formulations. 
When the model drug was changed to metoclopramide hydrochloride, one 
significant difference was observed: the tlag values were significantly greater for 
the HPMC capsules than for the gelatine capsules (III, Table V). This difference 
in the tlag values was not reflected in other parameters reflecting absorption rate 
(Cmax, tmax, Cmax/AUC). A similar difference in the tlag values between the two 
capsule shell types was obtained also with rectal metoclopramide capsules diluted 
with lactose. The rectal HPMC capsules containing ibuprofen with lactose or 
HPMC polymers as the diluents also exhibited greater tlag values than the 
corresponding gelatine capsules. Therefore, it can be concluded that the capsule 
shell material rather than the physicochemical properties of drugs or diluents 
affect the disintegration properties of the capsules in the rectum.  
Here again, it can be assumed that, even though the absorption of 
metoclopramide from the rectally administered HPMC capsules diluted with 
HPMC K100 powder began later than from the corresponding gelatine capsules, 
the capsule shells could be regarded as interchangeable because there was no 
statistically significant difference in the amount of metoclopramide absorbed from 
the two capsule types. Moreover, the capsules were intended for prolonged-
release formulations, where rapid onset of action is not needed. 
5.2.3.2. Effect of diluent and route of administration 
The results obtained for the rectally administered ibuprofen capsules diluted with 
either lactose (I) or HPMC powder (II) are gathered in Table 7. The HPMC 
powders used as the diluent clearly prolonged the absorption of ibuprofen in vivo 
when compared with capsules diluted with lactose. The Cmax and Cmax/AUC values 
were lower and the tmax values were greater for the HPMC powder-based capsules 
than for the lactose-based capsules (Table 7). Unlike after oral administration of 
the ibuprofen capsules diluted with the HPMC powders, the HPMC powders did 
not affect the tlag values after the rectal administration of the same capsules when 
compared with the lactose-based capsules (Tables 5 and 7). 
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Table 7. Pharmacokinetic parameters of ibuprofen (single dose of 2x200 mg) following 
rectal administration of capsules containing lactose (I) or HPMC polymers of different 
viscosity grades (II) (n=7, mean ± S.D.). Parameters between the lactose-based and 
HPMC powder-based capsules were not tested statistically, since the capsules were taken 
by two different subject groups. There were no statistically significant differences 
between the capsules diluted with the HPMC powders.    
Diluent Capsule AUC (mgh/l) 
Cmax   
(mg/l) 
tmax          
(h) 
MRT      
(h) 
Cmax/AUC  
(h-1) 
tlag        
(h) 
t1/2        
(h) 
HPMC 83 ± 42 21 ± 9.1 3.1 ± 1.6 2.7 ± 0.75 0.27 ± 0.056 0.90 ± 0.38 1.9 ± 0.84 
Lactose 
gelatine 92 ± 44 19 ± 10 2.9 ± 0.93 3.3 ± 1.4 0.21 ± 0.060 0.60 ± 0.33 2.5 ± 1.1 
HPMC 140 ± 34 16 ± 6.3 7.1 ± 3.6 6.4 ± 3.1 0.12 ± 0.044 0.91 ± 0.22 2.4 ± 3.7 HPMC 
K100 gelatine 125 ± 50 16 ± 9.7 6.7 ± 3.8 13 ± 14 0.13 ± 0.070 0.58 ± 0.39 6.8 ± 9.0 
HPMC 114 ± 54 12 ± 7.0 4.9 ± 1.1 9.7 ± 10 0.12 ± 0.054 0.85 ± 0.46 5.1 ± 8.5 HPMC 
K4M gelatine 154 ± 80 14 ± 7.0 6.0 ± 2.0 36 ± 79 0.10 ± 0.042 0.65 ± 0.42 23 ± 55 
HPMC 111 ± 57 12 ± 3.9 5.0 ± 2.1 7.6 ± 6.1 0.14 ± 0.070 0.85 ± 0.29 3.9 ± 5.6 HPMC 
K15M gelatine 139 ± 59 11 ± 5.3 7.4 ± 3.6 7.0 ± 2.1 0.078 ± 0.012 0.43 ± 0.36 3.8 ± 3.1 
 
The capsules diluted with the HPMC powders, especially those containing HPMC 
K4M or K15M, could be regarded as extended-release capsules, since the t1/2 and 
MRT values were clearly increased (Table 7), which was not the case when the 
same capsules were administered orally (Table 5). The mean ibuprofen 
concentration in plasma barely exceeded the minimum therapeutic level, which is 
10 mg/l (II, Fig. 5). In spite of that, the AUC values for the capsules diluted with 
the HPMC powders were greater than those for the capsules diluted with lactose 
(Table 7). In addition, the AUC values for the rectal HPMC powder-based 
capsules were of the same magnitude as (or even higher than) those for the same 
capsules administered orally (Tables 5 and 7). These findings indicate that the 
replacement of lactose with HPMC polymer or the use of rectal administration do 
not decrease the amount of ibuprofen absorbed. Therefore, it can be concluded, 
that the hard capsules diluted with HPMC powders have potential for rectal use as 
extended-release formulations, although further optimisation of the formulation is 
needed in order to achieve a therapeutic drug level in plasma. However, the 
correct technique for insertion into the rectum is essential for the success of these 
capsules since, as was already seen with rectal ibuprofen capsules diluted with 
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lactose (I), one of the subjects failed in insertion of the first study formulation in 
the present study (II) and was excluded from the test.  
Changing the viscosity grade of the HPMC powder did not statistically 
significantly alter the biopharmaceutical characteristics of the ibuprofen 
formulations (II, Table 4). This is not in accordance with the in vitro dissolution 
tests, where the release of ibuprofen from capsules containing the HPMC K100 
powder as the diluent was greater than from the capsules containing the other two 
viscosity grades. In other words, the in vitro dissolution study was not as 
predictive for the rectal administration as for the oral administration of these 
capsules. 
Since the viscosity grade of the HPMC powder used as diluent had an 
insignificant effect on the pharmacokinetic parameters of rectal ibuprofen 
capsules, only the HPMC K100 polymer was utilised when the model drug was 
changed to metoclopramide hydrochloride. The results obtained for these 
capsules diluted with either lactose or HPMC K100 powder (III) are gathered in 
Table 8. The HPMC K100 polymer prolonged the release and subsequent 
absorption of metoclopramide when compared with the lactose-based capsules, 
which was seen in tmax and Cmax/AUC values (Table 8). The capsules could be 
regarded as slow-release rather than extended-release formulations since the t1/2 
values were practically unaffected. The high t1/2 and MRT value with wide 
variation for the HPMC capsules diluted with HPMC K100 powder (Table 8) is 
due to overestimation of the t1/2 and MRT values: two subjects had almost the 
same metoclopramide concentration in plasma at 12 and 24 h post-dose.  
Table 8. Pharmacokinetic parameters of metoclopramide (single dose of 10 mg) 
following rectal administration of capsules containing lactose or HPMC K100 powder 
(III) (n=8 for the lactose-based capsules and n=7 for the HPMC K100-based capsules, 
mean ±
 S.D.). Parameters between the lactose-based and HPMC powder-based capsules 
were not tested statistically since the capsules were taken by two different subject groups.    
Diluent Capsule AUC (ngh/ml) 
Cmax   
(ng/ml) 
tmax          
(h) 
MRT      
(h) 
Cmax/AUC  
(h-1) 
tlag        
(h) 
t1/2        
(h) 
HPMC 272 ± 153 40 ± 19 3.6 ± 0.52 7.0 ± 2.6 0.16 ± 0.021 1.1 ± 0.36 5.1 ± 2.0 
Lactose 
gelatine 287 ± 134 38 ± 13 2.8 ± 0.89 10 ± 7.2 0.14 ± 0.023 0.62 ± 0.17 7.4 ± 5.0 
HPMC 169 ± 60 15 ± 7.0 7.4 ± 3.4 23.3 ± 22 0.084 ± 0.024 1.9 ± 0.65 16 ± 16 HPMC 
K100 gelatine 206 ± 70 18 ± 5.8 6.3 ± 1.4 7.9 ± 4.2 0.089 ± 0.017 0.92 ± 0.28 5.2 ± 3.3 
 
The tlag values for the HPMC K100-based capsules are clearly greater than those 
for the lactose-based capsules. This is in contrast to the results obtained with 
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ibuprofen, where the tlag values remained almost the same even though the diluent 
was changed from lactose to HPMC polymers of different viscosities (Table 7). 
This difference between the two model drugs is probably due to the differences in 
the drug/HPMC ratios of the capsules, which was on average 60/40% (w/w) for 
the ibuprofen capsules and 4/96%(w/w) for the metoclopramide hydrochloride 
capsules (Table 4). Several studies have shown that the drug/HPMC ratio is one of 
the major factors controlling the release of drugs from HPMC matrices (Salomon 
et al., 1979; Alderman, 1984; Ford et al., 1985b, c). 
The AUC values for the metoclopramide hydrochloride capsules containing 
HPMC K100 as the diluent were clearly smaller than those for the lactose-based 
capsules (Table 8). In addition, the AUC values for the rectal HPMC K100-based 
capsules were smaller than those for the same capsules administered orally. This 
difference was statistically significant for the HPMC capsules, but not for the 
gelatine capsules (III, Table V). Also the Cmax values were significantly lower and 
the tmax values were significantly higher for the rectally administered HPMC 
K100-based HPMC and gelatine capsules than for the corresponding orally 
administered capsules. One reason for these differences may be the poor 
drug/HPMC ratio, i.e. the amount of HPMC powder may have been too great for 
the metoclopramide to dissolve in the rectal fluid and to absorb completely. In 
addition, it should be noted that the capsules may have migrated to the upper part 
of the rectum which is connected with the portal vein system, and the absorbed 
metoclopramide was exposed to first-pass metabolism. However, the absorption 
profiles of metoclopramide from the HPMC K100-based capsules compared with 
the lactose-based capsules (III, Figs. 6 and 7) indicate that these capsules have 
potential for proper prolonged-release formulations if the drug/HPMC ratio is 
optimised, e.g. by increasing the metoclopramide dose to 20 or 30 mg.  
5.3. In vitro oesophageal sticking tendency of the 
capsule shells (II) 
Numerous in vitro and in vivo studies have shown that gelatine capsules have a 
high tendency to adhere to the oesophagus (Marvola et al., 1982, 1983; Swisher et 
al., 1984; Al-Dujaili et al., 1986; Bailey et al., 1987; Wilson et al., 1988; Perkins 
et al., 1999). The volume of water swallowed and the position of the body when 
swallowing are important determinants of the oesophageal transit time of gelatine 
capsules (Hey et al., 1982; Channer and Virjee, 1985; Bailey et al., 1987). 
Delayed oesophageal drug transit may have two effects. Firstly, retention of the 
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dosage form in the oesophagus delays drug absorption, as drugs cannot easily pass 
through the stratified squamous epithelium of the oesophageal mucosa (Channer 
and Roberts, 1984, 1985). Secondly, oesophageal disorders may develop and this 
has been reported for over 70 drugs (Jaspersen, 2000).  
The probability of adhesion to the oesophageal mucosa is increased if the 
surface of the dosage form becomes sticky when in contact with water. Therefore, 
formulations containing gelatine or cellulose derivatives have been recognized as 
hazardous with respect to oesophageal attachment (Swisher et al., 1984). In the 
study conducted with capsules containing ibuprofen and lactose (I), both the 
HPMC and the gelatine capsules were suspected to have adhered to the 
oesophagus or to the upper parts of the stomach in one subject (different subject 
on each occasion). Therefore, the tendency of the HPMC capsules to stick to the 
oesophageal mucosa was compared to that of gelatine capsules using the isolated 
porcine oesophagus method developed in our laboratory (Marvola et al., 1982). 
The capsules were filled with lactose. The force needed to detach the HPMC 
capsules from the preparation was significantly (p<0.001) smaller than for the 
gelatine capsules (II, Fig. 1). In addition, some of the gelatine capsules adhered to 
the oesophagus so strongly that they broke up while being detached, whereas all 
of the HPMC capsules (n=10) remained undamaged. The lower sticking tendency 
of the HPMC capsules would evidently be an advantage. However, the in vitro 
method used is not fully comparable to human physiological conditions and it has 
been demonstrated to give unreliable results compared with human in vivo studies 
(McCargar et al., 2001). Therefore, further in vivo studies are needed to verify the 
sticking properties of the HPMC capsules. 
5.4. Gamma scintigraphic evaluation (IV) 
The gamma scintigraphic imaging method was utilised to obtain visual data about 
the fate (movement and disintegration) of the two different orally administered 
prolonged-release HPMC capsules in the human GI tract for 8 h. The capsules 
were filled with either HPMC K100 or K4M powder and samarium oxide was 
used as a label. The results were compared with the studies conducted with 
corresponding orally administered capsules containing either metoclopramide 
hydrochloride or ibuprofen as the model drug. The aim was to find out the main 
reason why the pharmacokinetic profiles of the model drugs change when the 
diluent was changed to a higher viscosity grade derivative, whether it is due to 
differences in the degradation time of the gel plugs formed in the GI tract or to 
  47 
 
differences in the GI transit rate of these two different formulations. Special 
attention was paid also to whether HPMC capsules adhere to the oesophagus. 
The HPMC capsules lodged in the oesophagus for 22 to 143 min on 4 of the 12 
occasions (IV, Table 1). The incidence of stagnation (33%) was quite high 
although the subjects took 180 ml of water. In addition, they remained in a sitting 
position for 30 s before lying down, which should be long enough since the transit 
time for hard gelatine capsules has been reported to range from 7 to 24 s (Bailey 
et al., 1987; Wilson et al., 1988; Perkins et al., 1994, 1999). The incidence of 
oesophageal stagnation for hard, size 00 gelatine capsules has been reported to be 
17% when ingested with 120 ml of water and 61% when ingested with only 15 ml 
of water (Bailey et al., 1987). In both cases the subjects were in the sitting 
position. In the supine position and with only 15 ml of water the incidence was 
67% for the hard size 0 gelatine capsules, but if the subjects swallowed the 
capsule in the sitting position and immediately thereafter lay down, none of the 
capsules attached (Channer and Roberts, 1984). In a scintigraphic study, 
analogous with the present one, it was found that in one of 10 subjects a hard size 
0 gelatine capsule stuck to the oesophagus for 1.75 h although the amount of 
water ingested was 180 ml (Säkkinen et al., 2004).  
The present results on the tendency of the HPMC capsules to stick to the 
oesophagus do not support the results obtained with the in vitro oesophageal 
preparation (II, Section 3.2.). McCargar et al. (2001) also reported poor 
correlation between the results of in vivo human studies and the in vitro method 
utilising a porcine oesophagus. However, the in vivo arrangement used in the 
present study clearly affected the sticking incidence, since all occurrences were on 
the first study day. It is possible that the subjects became aware that the capsules 
might attach to the oesophagus and so swallowed the capsule differently on the 
second study day; e.g. swallowed more water with the first gulp after taking the 
capsule or took a gulp before putting the capsule into their mouths. Therefore, the 
possible differences between gelatine and HPMC capsules need further 
investigation with a well-planned, double-blind, cross-over human study utilising 
gamma imaging. Until then, it is recommended that both gelatine and HPMC 
capsules should be ingested with plenty of water in an upright position, then 
remaining in that position for several minutes. 
There was no evidence of the capsules having adhered to the gastric mucosa 
and they were emptied from the stomach within 2 h after ingestion. There were no 
differences between the two viscosity grades of HPMC polymer in respect of 
gastric emptying time, small intestine transit time or large intestine arrival time 
(IV, Table 1). The small intestine transit time for HPMC K100-based capsules 
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averaged 2.5 ± 0.4 h, and the capsules arrived at the large intestine on average 2.8 
±
 0.5 h after administration, when the oesophageal residence time was ignored 
(IV, Table 1). The corresponding values for the HPMC K4M-based capsules were 
2.7 ± 0.8 h and 3.2 ± 0.9 h, respectively. 
The viscosity grade of the HPMC polymer did not significantly affect the time 
at which samarium oxide started to be released from the formulations. The time 
for initial samarium oxide release from the HPMC K100-based capsules was on 
average 49 ± 20 min, and from the HPMC K4M-based capsules 53 ± 12 min (IV, 
Table 2). The division of the capsules into two or three pieces while drifting 
through the small and the large intestine also occurred at almost the same time for 
both capsule formulations (IV, Table 2). 
The difference between the two viscosity grades was obvious when complete 
capsule disintegration was examined. Five of the six HPMC K100-based capsules 
disintegrated completely during the study, whereas all of the HPMC K4M-based 
capsules still exhibited plug formations in the last images taken 8 h after 
administration (IV, Table 2). Due to the complete disintegration of the HPMC 
K100-based capsules, they spread better in the ascending colon than the HPMC 
K4M-based capsules (IV, Fig 2). In addition, the plug formations of the capsules 
at the end of the test were detected in the upper parts of the ascending colon or in 
the transverse and descending colon. Thus, the HPMC K100-based capsule may 
serve better the absorption of drugs from the colon than the HPMC K4M-based 
capsules since the absorptive capacity of the ascending colon is greater than that 
of the transverse and descending colon.  
When the results presented here are compared with the pharmacokinetic studies 
conducted with corresponding capsules containing metoclopramide hydrochloride 
as a model drug, it can be concluded that most of the metoclopramide dose was 
probably absorbed from the large intestine. The time to maximum drug 
concentration in plasma (tmax) was 4.2 and 4.7 h for the HPMC K100- and K4M-
based formulations, respectively (Section 5.2.2., Table 6). When the concentration 
versus time curves of metoclopramide are examined, the greatest portion of the 
area under the concentration time curves (AUC) for both capsule types may have 
been formed when the capsules were situated in the large intestine (III, Fig. 7). 
The same observations were made also with ibuprofen even though the 
drug/HPMC ratio was different (II, Table 3 and Fig. 3). Therefore, it appears that 
for the capsule types tested here, under fasting conditions, the large intestinal 
absorption governs the success of the capsules, and these capsules may not be 
suitable for drugs that are absorbed only from the small intestine or are poorly 
absorbed from the large intestine. The faster disintegration of the HPMC K100-
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based capsules compared with the HPMC K4M-based capsules explains why the 
maximum concentration (Cmax) of the model drugs, metoclopramide and 
ibuprofen, was significantly higher for the HPMC K100-based capsules than for 
the HPMC K4M-based capsules (II, Table 3; III, Table V). 
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6. Conclusions 
The main objective of the studies reported here was to evaluate the bio-
pharmaceutical properties of the novel hard HPMC capsules in comparison with 
hard gelatine capsules and to determine whether the two types of capsule shell 
could be regarded as interchangeable from the biopharmaceutical point of view.  
 
The following conclusions can be drawn from the present studies: 
 
• When the capsules were diluted with lactose, the oral absorption of the model 
drugs, ibuprofen and metoclopramide, from the different capsule shell types 
was similar and the HPMC and gelatine capsules could be regarded as 
interchangeable. When the same capsule formulations were administered 
rectally, the time lapse to the commencement of ibuprofen or metoclopramide 
absorption was greater for the HPMC capsules than for the gelatine capsules. 
This result is in accordance with in vitro dissolution. Nevertheless, since the 
change in the capsule shell material did not affect statistically significantly the 
bioavailability (AUC) of the model drugs, the HPMC capsules could be 
regarded as a noteworthy alternative to the gelatine capsules also for rectal 
administration if rapid onset of action is not required. 
 
• When HPMC and gelatine capsules filled with HPMC powders of various 
viscosities were administered orally, there were no differences between the 
HPMC and gelatine capsule shells that would have any significance in 
practice, regardless of the model drug. Therefore, from a biopharmaceutical 
point of view, the capsule shells could be regarded as interchangeable for oral 
use also when they are diluted with HPMC powders. When the same capsules 
were administered rectally, the difference between the HPMC and gelatine 
capsules was similar to that seen for capsules diluted with lactose: the time 
lapse to the commencement of ibuprofen or metoclopramide absorption was 
greater for the HPMC capsules than for the gelatine capsules. Nevertheless, 
since the bioavailability of the model drugs remained unaffected and the 
capsules were intended for prolonged release without need for rapid action, 
the HPMC capsules could be regarded as an alternative to gelatine capsules 
also when employing rectal administration. 
  51 
 
• The different chemical nature and water solubility of the model drugs did not 
have any marked effect on the in vitro and in vivo behaviour of the two 
capsule shell types, which further confirms the conclusion that these capsule 
shells could be regarded as interchangeable from a biopharmaceutical point of 
view. 
 
• Changing the diluent from lactose to HPMC powders of different viscosities 
prolonged the release of the model drugs after both oral and rectal 
administration. In addition, it was possible to control the release and 
subsequent absorption of the model drugs by changing the viscosity grade of 
the HPMC polymer, but this was valid only for oral formulations. A 
noteworthy observation was that changing the diluent from lactose to HPMC 
polymer did not reduce the oral or rectal bioavailability of the model drugs, 
except in the case of rectal capsules containing metoclopramide 
hydrochloride. In contrast, the bioavailable amount (AUC) from the HPMC 
powder-based capsules was in some cases even greater than from the lactose-
based capsules, regardless of the route of administration. These findings 
indicate that it is possible to produce prolonged-release capsule formulations 
easily and economically by simply filling the capsules with a proper swellable 
hydrophilic polymer. However, further optimisation of the formulations 
containing HPMC powders is needed in order to achieve a longer elimination 
half-life of the drug and, consequently, to lengthen the dose interval of the 
formulations.  
 
• The hard capsules turned out to be of value for rectal administration, 
especially when the model drug was metoclopramide hydrochloride and the 
diluent was lactose. Via the rectal route it was possible, at least partially, to 
avoid the first-pass metabolism of metoclopramide in the liver. However, the 
correct technique for insertion of the rectal capsules is essential for the success 
of this dosage form. In addition, product development is needed to minimise 
the time lapse to the onset of drug absorption, especially for HPMC capsules. 
 
• The tendency of the HPMC capsules to stick to the isolated porcine 
oesophagus was lower than that of the gelatine capsules. However, gamma 
scintigraphic investigations showed that the tendency of the HPMC capsules 
to stick to the human oesophagus is high, although further investigations of 
this phenomenon are needed in comparison with gelatine capsules. Until then, 
it is recommended that HPMC capsules, as well as gelatine capsules, should 
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be ingested with plenty of water in an upright position and remaining in that 
position for several minutes. 
 
• The gamma scintigraphic evaluation of the HPMC capsules containing either 
HPMC K100 or K4M powder as a diluent revealed that the main absorption 
site of drugs from these capsule formulations is the large intestine. Therefore, 
these capsules may not be suitable for drugs that are absorbed only from the 
small intestine or are poorly absorbed from the large intestine. The faster 
disintegration of the HPMC K100-based capsules explains why the absorption 
of the model drugs from these capsules was less sustained than from the 
HPMC K4M-based capsules. 
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